var title_f37_1_37904="Doxepin: Patient drug information";
var content_f37_1_37904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doxepin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/8/40069?source=see_link\">",
"       Doxepin (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/23/20852?source=see_link\">",
"       Doxepin (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12399 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37904=[""].join("\n");
var outline_f37_1_37904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/8/40069?source=related_link\">",
"      Doxepin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/23/20852?source=related_link\">",
"      Doxepin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37905="Patient information: Coma (The Basics)";
var content_f37_1_37905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/47/8947\">",
"         Patient information: Closed head injury (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/53/39761\">",
"         Patient information: Pressure sores (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Coma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/coma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H562954210\">",
"      <span class=\"h1\">",
"       What is a coma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A coma is a deep state of unconsciousness. A person in a coma:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Looks like he or she is asleep",
"       </li>",
"       <li>",
"        Cannot be woken up",
"       </li>",
"       <li>",
"        Cannot move at will",
"       </li>",
"       <li>",
"        Does not respond to pain or react when spoken to, touched, or shaken",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People in a coma sometimes twitch, move a hand or finger, or make faces or sounds, but that does not mean they are aware, awake, or in control.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562954225\">",
"      <span class=\"h1\">",
"       What causes a coma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A coma can be caused by anything that disrupts normal brain function. Some of the most common causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Head injury",
"       </li>",
"       <li>",
"        Stroke or bleeding in the brain",
"       </li>",
"       <li>",
"        Brain tumors",
"       </li>",
"       <li>",
"        Very low blood sugar or other chemical imbalances in the body",
"       </li>",
"       <li>",
"        Poisoning, or drug or alcohol overdose",
"       </li>",
"       <li>",
"        Lack of oxygen or blood to brain, which could happen if a person&rsquo;s heart stopped or the person almost drowned",
"       </li>",
"       <li>",
"        Infections such as meningitis or encephalitis",
"       </li>",
"       <li>",
"        Seizures",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562954240\">",
"      <span class=\"h1\">",
"       How do doctors find the cause of a coma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a person is unconscious, his or her doctors and nurses will do an exam to see how the person responds to touch and pain, and to see how the person&rsquo;s eyes respond to light. Then, they will order tests, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Imaging tests of the brain &ndash; These tests create pictures of the brain and can show if any parts of the brain are damaged. Examples of these tests include CT scans and MRIs.",
"       </li>",
"       <li>",
"        EEG (which stands for electroencephalogram) &ndash; An EEG measures the electrical activity in the brain. It can measure brain waves and show how deeply unconscious a person is.",
"       </li>",
"       <li>",
"        Lumbar puncture (also called a &ldquo;spinal tap&rdquo;) &ndash; For this test, a doctor puts a thin needle into the person&rsquo;s lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. The spinal fluid goes to the lab for tests.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562954255\">",
"      <span class=\"h1\">",
"       How is a coma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The only way to get a person out of a coma is to reverse the condition that caused it. That is not always possible. If it is possible, it needs to be done right away to prevent death and permanent brain damage.",
"     </p>",
"     <p>",
"      When it is not possible to get someone out of a coma, doctors try to at least make sure the person keeps breathing and still has a heartbeat. To do that, they hook the person up to machines that monitor heart rate and breathing. That way, the medical team can respond right away if anything goes wrong. Some people who are in a coma need to be put on a machine that breathes for them.",
"     </p>",
"     <p>",
"      People in a coma also:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get medicines to help control basic body functions, such as blood pressure, heart rate, and body temperature",
"       </li>",
"       <li>",
"        Get fed through an IV (a tube that goes into a vein) or a stomach tube",
"       </li>",
"       <li>",
"        Get moved every so often so that they do not develop sores on their body",
"       </li>",
"       <li>",
"        Have routine blood tests done often, so the doctors and nurses can look for signs of infection or other problems",
"       </li>",
"       <li>",
"        Have their reflexes and responses to pain checked every so often",
"       </li>",
"       <li>",
"        Have their temperature checked",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562954270\">",
"      <span class=\"h1\">",
"       How long can a coma last?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people who are in a coma come out of it in 2 to 4 weeks. Comas are not permanent and do not usually last more than several weeks. Patients either recover completely or partially, or die.",
"     </p>",
"     <p>",
"      Some people with severe brain injury transition from a coma to something called a &ldquo;persistent vegetative state.&rdquo; People in a persistent vegetative state have brain activity that suggests they go to sleep and wake up but otherwise seem like they are in a coma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H562954287\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"       Patient information: Closed head injury (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/53/39761?source=see_link\">",
"       Patient information: Pressure sores (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/1/37905?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83678 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37905=[""].join("\n");
var outline_f37_1_37905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562954210\">",
"      What is a coma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562954225\">",
"      What causes a coma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562954240\">",
"      How do doctors find the cause of a coma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562954255\">",
"      How is a coma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562954270\">",
"      How long can a coma last?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H562954287\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/53/39761?source=related_link\">",
"      Patient information: Pressure sores (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37906="Scorpion anatomy";
var content_f37_1_37906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Scorpion anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scorpion has a lobster-like body shape with seven sets of paired appendages: the chelicerae, the pedipalps (claws or pinchers), four sets of legs, and the pectines (comb-like structures on the ventral surface). The segmented tail curves up dorsally, ending in the terminal bulbous segment called the telson, which contains paired venom glands and the aculeus (stinger).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37906=[""].join("\n");
var outline_f37_1_37906=null;
var title_f37_1_37907="Patient information: How to plan and prepare for a healthy pregnancy (The Basics)";
var content_f37_1_37907=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/42/24226\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/46/17122\">",
"         Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/39/33395\">",
"         Patient information: Avoiding infections in pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/62/31714\">",
"         Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/40/22146\">",
"         Patient information: Lead poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/56/37762\">",
"         Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/52/8003\">",
"         Patient information: Vaccines and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/52/43843\">",
"         Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/45/10966\">",
"         Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/7/17522\">",
"         Patient information: Vaccination during pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/how-to-plan-and-prepare-for-a-healthy-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13010281\">",
"      <span class=\"h1\">",
"       Should I see a doctor before I try to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It's very important that you see your doctor or nurse for a &ldquo;pre-pregnancy check-up.&rdquo; Your doctor or nurse will ask you about things that could affect your pregnancy. For instance, he or she might ask about your diet, lifestyle, use of birth control, past pregnancies, medicines, and any diseases that you have or that run in your family.",
"     </p>",
"     <p>",
"      There are several things that you and your doctor or nurse can do to make sure that your pregnancy is as healthy as possible. These things should be done BEFORE you try to get pregnant:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Discuss any medicines or herbal drugs you take and find out if you need to make changes",
"       </li>",
"       <li>",
"        Discuss whether you are up-to-date on your vaccines",
"       </li>",
"       <li>",
"        Start taking a multivitamin that has",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        (also called folate)",
"       </li>",
"       <li>",
"        Know which foods you should avoid and which foods are best",
"       </li>",
"       <li>",
"        Stop smoking, drinking alcohol, or taking illegal drugs",
"       </li>",
"       <li>",
"        Understand the risks to you and your baby if:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        You have any medical conditions",
"       </li>",
"       <li>",
"        There are diseases that run in your family or your partner's family",
"       </li>",
"       <li>",
"        There is a chance you have an infection that people catch during sex (called a sexually transmitted disease)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Discuss whether there are any harmful substances in your home or work",
"       </li>",
"       <li>",
"        Try to reach a healthy weight",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Each of these issues is explained in more detail below.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010288\">",
"      <span class=\"h1\">",
"       Ask if the medicines you take are safe",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take any medicines, supplements, or herbal drugs, ask your doctor if it is safe to keep taking them while you are pregnant or trying to get pregnant. Some medicines take a long time to leave your body completely, so it's important to plan ahead. In some cases, your doctor and nurse will want you to switch to different medicines that are safer for the baby. Your doctor and nurse may need to slowly get you off some medicines because it could harm you to stop them all of a sudden. This is especially important for women who take medicines to treat seizures, high blood pressure, lupus, and rheumatoid arthritis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010295\">",
"      <span class=\"h1\">",
"       Check if you need any vaccines",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who want to get pregnant should be up-to-date on their vaccines. This includes vaccines against measles, mumps, rubella, tetanus, diphtheria, polio, chickenpox (also called varicella), and possibly hepatitis. Many women got these vaccines as children. Still, it is important to check that you have had all the right vaccines. Otherwise, you could get sick with the diseases the vaccines protect against, and that could cause problems for you or your baby. All women should also get a flu shot every year.",
"     </p>",
"     <p>",
"      Some vaccines cannot be given during pregnancy or in the month before pregnancy. It's important to get these vaccines more than a month before you start trying to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010302\">",
"      <span class=\"h1\">",
"       Start taking a multivitamin",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, take a &ldquo;prenatal&rdquo; multivitamin every day that has at least 400 micrograms of",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      . This helps prevent some birth defects. Start taking the multivitamin at least a month before you start trying to get pregnant. It&rsquo;s not enough to start taking vitamins when you find out you are pregnant. At that point, your baby has already formed many body parts that rely on folic acid and other vitamins to develop normally.",
"     </p>",
"     <p>",
"      It is important not to take too much of any vitamin during pregnancy, especially vitamin A. Show your doctor or nurse the vitamins you plan to take to make sure the doses are safe for you and your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010309\">",
"      <span class=\"h1\">",
"       Check your diet",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some foods are not safe for a woman who is pregnant or trying to get pregnant. If you are trying to get pregnant, do not eat raw or undercooked meat. Avoid eating shark, swordfish, king mackerel, or tilefish because they can have high levels of mercury. Check with your doctor or nurse about the safety of fish caught in local rivers and lakes. Limit the amount of caffeine you have by not drinking more than 1 or 2 cups of coffee, tea, or cola each day. Try to eat a balanced diet rich in fruits, vegetables, and whole grains. Wash fruits and vegetables before eating them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010316\">",
"      <span class=\"h1\">",
"       Stop smoking, drinking alcohol, or taking illegal drugs",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you smoke, drink alcohol, or take illegal drugs, now more than ever it is important that you stop. Using even small amounts of these substances from time to time during pregnancy could hurt your baby.",
"     </p>",
"     <p>",
"      It&rsquo;s not enough to stop as soon as you find out you are pregnant. By then the baby has already begun to form and could get damaged by smoking, alcohol, or drugs. If you need help quitting, speak with your doctor or nurse. There are effective treatments that can help.",
"     </p>",
"     <p>",
"      Your partner should also stop smoking and using illegal drugs. He should not drink too much alcohol.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010323\">",
"      <span class=\"h1\">",
"       Ask about risks",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor what the risks to you and your baby might be if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         You have any medical conditions",
"        </strong>",
"        &mdash; If you have a medical problem, it could cause problems for you or your baby during pregnancy. Women who have certain medical conditions should work with their doctor to get their conditions under control before they get pregnant. This includes women with diabetes, high blood pressure, asthma, thyroid conditions, seizure disorders, and other problems. If these conditions are not well controlled, they can cause problems for a mother and her baby during pregnancy.",
"       </li>",
"       <li>",
"        <strong>",
"         You or your partner has a family history of a medical condition",
"        </strong>",
"        &mdash; If you or your partner has a history of a condition that could be passed on to your baby, you might need genetic counseling. Genetic counseling can help you find out what the chances are that your baby will have the condition. It will also help you sort out what your options might be if your baby does have problems. Examples of conditions that might call for genetic counseling include cystic fibrosis and muscular dystrophy.",
"       </li>",
"       <li>",
"        <strong>",
"         You might have an infection that you catch through sex &mdash;",
"        </strong>",
"        Infections that you can catch through sex, also called",
"        <strong>",
"        </strong>",
"        &ldquo;sexually transmitted diseases,&rdquo; or &ldquo;STDs,&rdquo; can make it hard to get pregnant. They can also infect and harm an unborn baby. If you think you might have 1 of these infections, tell your doctor or nurse. He or she can test for the infection and treat it. This is especially important if there is a chance of HIV infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010330\">",
"      <span class=\"h1\">",
"       Check your home and work for harmful substances",
"      </span>",
"      &nbsp;&mdash;&nbsp;People often have chemicals or substances in their home or work that could hurt an unborn baby. Dealing with these substances can sometimes be complicated and time consuming, so it&rsquo;s important to plan ahead. For instance, people who live in homes built before 1978 often have lead paint on their walls or woodwork. Lead in chips or dust from this paint could harm a baby. Ask your doctor or nurse how to deal with this and other harmful substances you might have around you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010337\">",
"      <span class=\"h1\">",
"       Work on your weight",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who weigh too little or too much can have problems getting pregnant and problems during pregnancy. You should try to reach a healthy weight before you try to get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13010493\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=see_link\">",
"       Patient information: Vaccines and pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=see_link\">",
"       Patient information: Avoiding infections in pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/62/31714?source=see_link\">",
"       Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22146?source=see_link\">",
"       Patient information: Lead poisoning (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/56/37762?source=see_link\">",
"       Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/46/17122?source=see_link\">",
"       Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=see_link\">",
"       Patient information: Vaccination during pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/52/43843?source=see_link\">",
"       Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"       Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/1/37907?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16247 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37907=[""].join("\n");
var outline_f37_1_37907=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010281\">",
"      Should I see a doctor before I try to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010288\">",
"      Ask if the medicines you take are safe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010295\">",
"      Check if you need any vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010302\">",
"      Start taking a multivitamin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010309\">",
"      Check your diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010316\">",
"      Stop smoking, drinking alcohol, or taking illegal drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010323\">",
"      Ask about risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010330\">",
"      Check your home and work for harmful substances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010337\">",
"      Work on your weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13010493\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/46/17122?source=related_link\">",
"      Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/52/43843?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22146?source=related_link\">",
"      Patient information: Lead poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/56/37762?source=related_link\">",
"      Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=related_link\">",
"      Patient information: Vaccination during pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=related_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37908="Inguinal hernia on computed tomography";
var content_f37_1_37908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Inguinal hernia on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) scan of through the femoral heads (A) shows a large hernia&nbsp;(arrowhead) medial to the pubic tubercle (arrow).&nbsp;In spite of the size of the hernia, there is no evidence for left femoral vein compression (dashed arrow), which helps to distinguish this inguinal hernia&nbsp;from a femoral hernia. The hernia is of sufficient volume to displace the base of the penis (short arrow, B). Fat (arrowhead) and small bowel (thick arrow) are present in the hernia sac (B). Artifact across the pelvis is caused by bilateral hip replacements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37908=[""].join("\n");
var outline_f37_1_37908=null;
var title_f37_1_37909="Breast intraductal papilloma ultrasound";
var content_f37_1_37909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Breast intraductal papilloma ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ultrasound of left breast shows a solitary dilated duct (A, red arrow) with a filling defect consisting of soft tissue echoes within the duct (B, overlaid in green). These findings are consistent with a benign papilloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37909=[""].join("\n");
var outline_f37_1_37909=null;
var title_f37_1_37910="Atopic keratoconjunctivitis";
var content_f37_1_37910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atopic keratoconjunctivitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Pedram Hamrah, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Reza Dana, MD, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37910/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/1/37910/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five main types of ocular allergy: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). VKC and AKC are chronic, bilateral, and severe forms of allergic inflammation affecting the ocular surface. These two relatively uncommon types of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly. Type I hypersensitivity reactions are important in these diseases, although they are not the only pathophysiologic mechanism.",
"   </p>",
"   <p>",
"    The term AKC is not ideal, as it is not specific and does not by itself differentiate AKC from other forms of atopic eye disease. AKC in general refers to a \"perennial\" form of allergic conjunctivitis (AC) that also has potential significant corneal involvement, where as VKC is the \"seasonal\" form (at least initially) of AC that may affect the cornea. AKC is reviewed in this topic. VKC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link\">",
"     \"Vernal keratoconjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GPC is an inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It develops with protracted use of topical medications, mostly due to preservatives. GPC and toxic conjunctivitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5062?source=see_link\">",
"     \"Giant papillary conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6452?source=see_link\">",
"     \"Toxic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seasonal and perennial allergic conjunctivitis, the most common forms of ocular allergy, are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKC is a chronic allergic ocular disease that occurs most often in patients with a history of atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The exact prevalence is unknown. However, 4.4 percent of 1079 patients with ocular allergy had AKC in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/3\">",
"     3",
"    </a>",
"    ]. Another study demonstrated that 77 percent of patients with atopic dermatitis (AD) suffered from AKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/4\">",
"     4",
"    </a>",
"    ], although a subsequent series noted lower rates of AKC in patients with AD, in the range of 20 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AKC primarily affects adults. Symptoms most commonly begin in the second and third decades, with a peak incidence between 30 and 50 years of age. This is in contrast to VKC, in which the peak incidence is between 7 and 12 years of age. However, onset of symptoms of AKC have been described between 7 and 76 years of age. AKC has a male:female ratio of 2.4:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/1\">",
"     1",
"    </a>",
"    ]. Personal and family histories are almost always positive for atopy (more commonly atopic dermatitis and asthma than allergic rhinitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKC consists of type IV (delayed-type) hypersensitivity reactions and some involvement of type I hypersensitivity. There are increased numbers of mast cells, eosinophils, CD4+ T cells, monocytes, and fibroblasts in the conjunctiva compared with normal individuals (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Histology'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The strong upregulation of HLA-DR in the epithelium and substantia propria shown by immunohistochemistry suggests a role in antigen presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated levels of IgE are observed in the tears and serum of AKC patients compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/6\">",
"     6",
"    </a>",
"    ]. However, only about one-half of patients with AKC test positive to specific allergens. Those that are sensitized to aeroallergens tend to be positive to multiple allergens. Tears contain CD4+ T cells and B cells and increased levels of the cytokines IFN-gamma, TNF-alpha, IL-4, IL-5, and IL-10 and the chemokine eotaxin compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ]. Patients with AKC may show dysfunctional cell-mediated immunity, and occasionally have lower levels of circulating T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly reported symptom of AKC is intense itching, which can occur perennially or only in certain seasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Tearing, clear mucus discharge, and redness are also almost always present.",
"   </p>",
"   <p>",
"    Other symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blurry vision",
"     </li>",
"     <li>",
"      Burning",
"     </li>",
"     <li>",
"      Photophobia",
"     </li>",
"     <li>",
"      Foreign body sensation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKC can involve the eyelid, conjunctiva, and cornea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. There is a wide range of severity, from mild isolated eyelid involvement to sight-threatening corneal involvement. The severity can also be highly asymmetric even though involvement is typically bilateral.",
"   </p>",
"   <p>",
"    Eyelid changes in AKC are usually quite striking (",
"    <a class=\"graphic graphic_picture graphicRef56670 \" href=\"mobipreview.htm?14/15/14579\">",
"     picture 1",
"    </a>",
"    ). Characteristic findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thickened eyelids",
"     </li>",
"     <li>",
"      Intermittent swelling of the eyelids due to chronic inflammation",
"     </li>",
"     <li>",
"      A profound scaly and indurated appearance to the periocular skin, with flaking dermatitis and a reddened base",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eyelids may become lichenified and woody, developing cicatricial ectropion (lower eyelid turns outward or everts due to scarring) and lagophthalmos (failure to close the eyelids completely). Fissures, superciliary madarosis (loss of eyelashes), lateral canthal ulceration, and ptosis can sometimes develop as well. Lid margins may show meibomianitis, keratinization, and punctal ectropion (lacrimal puncta is everted). Blepharitis caused by staphylococcal bacteria is also common. Eye rubbing is almost always reported.",
"   </p>",
"   <p>",
"    Chronic ocular surface inflammation can lead to vision loss (",
"    <a class=\"graphic graphic_picture graphicRef69396 \" href=\"mobipreview.htm?17/39/18033\">",
"     picture 2",
"    </a>",
"    ). Signs of chronic ocular surface inflammation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conjunctival chemosis",
"     </li>",
"     <li>",
"      Conjunctival hyperemia",
"     </li>",
"     <li>",
"      Tarsal papillary hypertrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The papillary hypertrophy in AKC is more prominent in the inferior fornix. This is in contrast to vernal keratoconjunctivitis (VKC) and giant papillary conjunctivitis (GPC), in which papillary formation occurs on the upper lids. In addition, papillae may form adjacent to the cornea as perilimbal gelatinous hyperplasia. Subepithelial fibrosis is common, but forniceal shortening and symblepharon (adhesion of the eyelid to the globe) may also form.",
"   </p>",
"   <p>",
"    Other issues that involve the cornea with AKC and can lead to significant vision loss include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Corneal neovascularization",
"     </li>",
"     <li>",
"      Dry eyes",
"     </li>",
"     <li>",
"      Infectious and sterile ulcers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other eye disorders that are associated with AKC include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Corneal thinning disorders",
"     </li>",
"     <li>",
"      Herpetic keratitis",
"     </li>",
"     <li>",
"      Retinal detachment",
"     </li>",
"     <li>",
"      Several forms of cataracts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of corticosteroids frequently causes worsening of cataracts in these patients. Long-term eye rubbing may or may not contribute to the other eye disorders associated with AKC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conjunctival epithelial layer is thickened in AKC. The conjunctival epithelium and substantia propria of AKC patients show elevated numbers of mast cells and eosinophils; increased fibroblast numbers and collagen amount; and an increased",
"    <span class=\"nowrap\">",
"     CD4+/CD8+",
"    </span>",
"    ratio of T cells compared with normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/6-8,14\">",
"     6-8,14",
"    </a>",
"    ]. In addition, large numbers of mononuclear cells are present in the substantia propria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established diagnostic criteria or laboratory tests for AKC. The diagnosis of AKC is based upon the typical epidemiology and clinical features of AKC (eg, adults with a history of atopic dermatitis who present with ocular pruritus, eyelid dermatitis, and giant papillae on the conjunctival lining of the lower tarsus and inferior fornix). A clinical grading system was proposed to aid in the diagnosis and management of AKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Physical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main disease to consider in the differential diagnosis is vernal keratoconjunctivitis (VKC). However, in contrast to AKC, VKC occurs in prepubertal boys from warm climates, symptoms are most often seasonal initially, and the upper tarsus (eyelid) is predominantly affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients with AKC is multi-pronged and includes topical and systemic medications, as well as nonpharmacologic therapies.",
"   </p>",
"   <p>",
"    Nonpharmacologic measures include avoidance of nonspecific",
"    <span class=\"nowrap\">",
"     triggers/environmental",
"    </span>",
"    irritants, eye rubbing, and known allergens (in patients with IgE-mediated disease) and use of cold compresses and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    . Punctal plugs are also used to prevent eye dryness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H10#H10\">",
"     \"Vernal keratoconjunctivitis\", section on 'Nonpharmacologic measures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link\">",
"     \"Dry eyes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical antihistamines and mast cell stabilizers are generally the first line pharmacologic therapies. Treatment with topical corticosteroids is best undertaken by an ophthalmologist. Patients who do not respond to these therapies may benefit from an allergy evaluation and possibly allergen immunotherapy, although data on efficacy are lacking. Additional medications that may be effective in some patients include topical and systemic calcineurin inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=see_link&amp;anchor=H17#H17\">",
"     \"Allergic conjunctivitis\", section on 'Stepwise approach to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mast cell stabilizers and dual acting agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical mast cell stabilizers are typically used as daily, long-term, prophylactic therapy. Patients with perennial symptoms are treated year round. The use of 2 percent sodium cromolyn reduced itching, tearing, and photophobia in one double-blind, crossover trial, but was ineffective in another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Dual acting mast cell",
"    <span class=\"nowrap\">",
"     stabilizers/antihistamines",
"    </span>",
"    (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5555?source=see_link\">",
"     lodoxamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     ketotifen",
"    </a>",
"    ) may be helpful as well, although there are no randomized trials or observational studies using these drugs in AKC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H11#H11\">",
"     \"Vernal keratoconjunctivitis\", section on 'Topical antihistamines and mast cell stabilizers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an ophthalmologist is highly recommended for patients who do not respond to two or three weeks of consistent therapy with an",
"    <span class=\"nowrap\">",
"     antihistamine/mast",
"    </span>",
"    cell stabilizer agent, since pulse therapy with topical corticosteroids is typically the next step.",
"   </p>",
"   <p>",
"    There are few data on the efficacy of topical corticosteroids in treating AKC. In a double-blind trial of 38 patients with AKC, topical 2 percent sodium cromoglycate was applied every six hours in one eye and 1 percent medrysone in the contralateral eye for four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/16\">",
"     16",
"    </a>",
"    ]. Medrysone significantly improved itching, watering, photophobia, and hyperemia (improved by 76, 64, 81, and 73 percent, respectively), whereas cromolyn had little effect (improved by 12, 4, 7, and 2 percent, respectively). As with VKC, application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    acetate eight times per day for approximately one week is generally used for severe exacerbations, and twice per day dosing for two weeks of a \"soft\" steroid, such as medrysone is used in milder cases. \"Soft\" corticosteroids have a lower risk of raising intraocular pressure. The use of topical corticosteroids should be transient and monitored carefully. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H12#H12\">",
"     \"Vernal keratoconjunctivitis\", section on 'Topical corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical calcineurin inhibitors are generally used as steroid-sparing agents. Unlike corticosteroids, these medications do not increase intraocular pressure. In one small randomized trial, topical therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    2 percent four times daily was more effective than placebo in reducing topical corticosteroid use and improving signs and symptoms in patients with AKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/17\">",
"     17",
"    </a>",
"    ]. Lower concentrations of cyclosporine have shown mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In a case series, continuous therapy with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    led to moderate to marked improvement in the signs of AKC in patients with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H14#H14\">",
"     \"Vernal keratoconjunctivitis\", section on 'Calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment of eyelid dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of AKC also includes therapy for eyelid dermatitis. Topical application of a low-potency corticosteroid to the eyelids two to four times per day for several weeks may be required to suppress the allergic process in the periocular skin. However, patients should be warned that prolonged use of corticosteroids on the skin can lead to dermal thinning. Additionally, these patients should be monitored by an ophthalmologist for ocular side effects because of the permeability of corticosteroids through the skin.",
"   </p>",
"   <p>",
"    An alternative to topical corticosteroids for treatment of eyelid dermatitis is topical calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In a randomized crossover trial, there was a nonsignificant trend toward superior benefit of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in reducing signs and symptoms of eyelid eczema compared with a topical corticosteroid, clobetasone, in patients with AKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/22\">",
"     22",
"    </a>",
"    ]. Ocular signs and symptoms also improved with topical tacrolimus therapy restricted to the eyelids in several case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Systemic immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKC, unlike the milder forms of allergic eye disease, is a chronic and aggressive form of ocular surface inflammation associated with sight-threatening fibrosis. Thus, systemic immunosuppressive therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) is sometimes used in severe cases in which topical corticosteroids are ineffective or are required for longer than six weeks. Three small case series found that long-term therapy with systemic calcineurin inhibitors (cyclosporine 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or tacrolimus 0.03 to 0.08",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) was generally safe and resulted in complete remission in most patients with severe, refractory AKC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Co-management with an ophthalmologist, internist, allergist, dermatologist,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rheumatologist is recommended to maximize the outcome and minimize side effects in these difficult cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral nonsedating antihistamines are effective in the treatment of allergic conjunctivitis, although no studies have been performed in patients with AKC. Activation of ocular H1 receptors via histamine is responsible for some AKC symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/2\">",
"       2",
"      </a>",
"      ], suggesting that oral antihistamines may be effective in these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H17#H17\">",
"       \"Vernal keratoconjunctivitis\", section on 'Oral antihistamines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasmapheresis was effective in two patients with AKC who had failed to respond to topical and oral corticosteroids and topical cromolyn [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consultation with an allergist for allergy testing and consideration of allergen immunotherapy is appropriate for patients with AKC. Allergy testing helps identify the offending allergen in about one-half of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/6\">",
"       6",
"      </a>",
"      ] and helps guide measures to limit exposure. Adequate control of environmental triggers is one of the most effective management tools for AKC. There is evidence that allergen immunotherapy improves symptoms of ocular allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37910/abstract/28\">",
"       28",
"      </a>",
"      ]. However, there are no reports demonstrating this specifically for AKC. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H10#H10\">",
"       \"Vernal keratoconjunctivitis\", section on 'Nonpharmacologic measures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link&amp;anchor=H9#H9\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Allergic rhinitis and conjunctivitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atopic keratoconjunctivitis (AKC), unlike the milder forms of allergic eye disease, is a chronic and aggressive form of ocular surface inflammation associated with sight-threatening fibrosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AKC primarily affects adults, with a peak incidence between 30 and 50 years of age. Patients commonly have a history of atopic dermatitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequently reported symptom of AKC is intense itching, which can occur perennially or only in certain seasons. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AKC can involve the eyelid, conjunctiva, and cornea. The severity can be highly asymmetric, even though involvement is typically bilateral. Eyelids are usually thickened and swell intermittently. There is a profound scaly and indurated appearance to the periocular skin, with flaking dermatitis and a reddened base. Ocular findings include conjunctival chemosis and hyperemia, and tarsal papillary hypertrophy in the inferior fornix. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no established diagnostic criteria or laboratory tests for AKC. The diagnosis of AKC is based upon the typical epidemiology and clinical features of AKC. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to patients with AKC includes topical and systemic medications, as well as nonpharmacologic therapies. Treatments other than first line therapies (eg, topical corticosteroids and calcineurin inhibitors and systemic immunosuppressive agents) should be initiated only in consultation with an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=see_link&amp;anchor=H10#H10\">",
"       \"Vernal keratoconjunctivitis\", section on 'Nonpharmacologic measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend a topical mast cell stabilizer as first line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives are a dual acting mast cell stabilizer and antihistamine or a combination of a separate topical mast cell stabilizer and a topical antihistamine. (See\" Topical antihistamines and mast cell stabilizers\" above).",
"     </li>",
"     <li>",
"      We recommend a short-term, high-dose pulse regimen of topical corticosteroids in patients with AKC who fail to respond to two to three weeks of a mast cell stabilizer or dual acting",
"      <span class=\"nowrap\">",
"       antihistamine/mast",
"      </span>",
"      cell stabilizer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Topical corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      2 percent as a corticosteroid-sparing agent in patients with moderate to severe disease who require frequent or prolonged courses of topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Topical calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating eyelid dermatitis with topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , rather than topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment of eyelid dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest systemic immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      in severe cases in which topical corticosteroids are ineffective or are required for longer than six weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Systemic immunosuppressive agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/1\">",
"      Tuft SJ, Kemeny DM, Dart JK, Buckley RJ. Clinical features of atopic keratoconjunctivitis. Ophthalmology 1991; 98:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/2\">",
"      Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology 1990; 97:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/3\">",
"      Uchio E, Kimura R, Migita H, et al. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol 2008; 246:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/4\">",
"      Moscovici BK, Cesar AS, Nishiwaki-Dantas MC, et al. [Atopic keratoconjunctivitis in patients of the pediatric dermatology ambulatory in a reference center]. Arq Bras Oftalmol 2009; 72:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/5\">",
"      Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am 2010; 30:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/6\">",
"      Bonini S. Atopic keratoconjunctivitis. Allergy 2004; 59 Suppl 78:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/7\">",
"      Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 2007; 7:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/8\">",
"      Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology 1991; 98:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/9\">",
"      Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006; 36:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/10\">",
"      Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003; 110:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/11\">",
"      Metz DP, Hingorani M, Calder VL, et al. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol 1997; 100:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/12\">",
"      Braude LS, Chandler JW. Atopic corneal disease. Int Ophthalmol Clin 1984; 24:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/13\">",
"      Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007; 7:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/14\">",
"      Soukiasian SH, Rice B, Foster CS, Lee SJ. The T cell receptor in normal and inflamed human conjunctiva. Invest Ophthalmol Vis Sci 1992; 33:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/15\">",
"      Jay JL. Clinical features and diagnosis of adult atopic keratoconjunctivitis and the effect of treatment with sodium cromoglycate. Br J Ophthalmol 1981; 65:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/16\">",
"      Vajpayee RB, Gupta SK, Uppal RK. Evaluation of sodium cromoglycate and medrysone in the management of atopic keratoconjunctivitis: a double masked clinical study. Aust N Z J Ophthalmol 1986; 14:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/17\">",
"      Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998; 105:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/18\">",
"      Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004; 111:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/19\">",
"      Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006; 90:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/20\">",
"      Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009; 25:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/21\">",
"      Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008; 115:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/22\">",
"      Nivenius E, van der Ploeg I, Jung K, et al. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond) 2007; 21:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/23\">",
"      Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/24\">",
"      Zribi H, Descamps V, Hoang-Xuan T, et al. Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol 2009; 23:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/25\">",
"      Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology 1997; 104:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/26\">",
"      Stumpf T, Luqmani N, Sumich P, et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 2006; 25:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/27\">",
"      Aswad MI, Tauber J, Baum J. Plasmapheresis treatment in patients with severe atopic keratoconjunctivitis. Ophthalmology 1988; 95:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37910/abstract/28\">",
"      Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002; 2:447.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5550 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37910=[""].join("\n");
var outline_f37_1_37910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mast cell stabilizers and dual acting agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment of eyelid dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Systemic immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5550|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/15/14579\" title=\"picture 1\">",
"      AKC eyelid changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/39/18033\" title=\"picture 2\">",
"      AKC ocular changes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5062?source=related_link\">",
"      Giant papillary conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/19/6452?source=related_link\">",
"      Toxic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37352?source=related_link\">",
"      Vernal keratoconjunctivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37911="Clinical features of primary aldosteronism";
var content_f37_1_37911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features of primary aldosteronism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37911/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/1/37911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia.",
"   </p>",
"   <p>",
"    Many subtypes of primary aldosteronism have been described since Conn's original report of the aldosterone-producing adenoma in 1954 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The most common subtypes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldosterone-producing adenoma",
"     </li>",
"     <li>",
"      Bilateral idiopathic hyperaldosteronism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common forms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unilateral hyperplasia or primary adrenal hyperplasia (caused by micronodular or macronodular hyperplasia of the zona glomerulosa of predominantly one adrenal gland)",
"     </li>",
"     <li>",
"      Bilateral macronodular or micronodular adrenal hyperplasia with primary aldosteronism",
"     </li>",
"     <li>",
"      Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism [GRA]) and type II (the familial occurrence of aldosterone-producing adenoma or bilateral idiopathic hyperplasia or both)",
"     </li>",
"     <li>",
"      Pure aldosterone-producing adrenocortical carcinomas and ectopic aldosterone-secreting tumors (eg, neoplasms in the ovary or kidney)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features of primary aldosteronism will be reviewed here. The treatment of this disorder and an approach to the diagnosis of hypertension and hypokalemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of primary aldosteronism are in part determined by the renal actions of aldosterone. The primary effect of aldosterone is to increase the number of open sodium channels in the luminal membrane of the principal cells in the cortical collecting tubule, leading to increased sodium reabsorption. The ensuing loss of cationic sodium makes the lumen electronegative, thereby creating an electrical gradient that favors the secretion of cellular potassium into the lumen through potassium channels in the luminal membrane (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The steady state",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described below, aldosterone-induced sodium retention is of limited duration and does not lead to edema because of \"aldosterone escape,\" in which an increase in sodium-wasting forces counteracts the sodium-retaining effect of excess aldosterone (",
"    <a class=\"graphic graphic_figure graphicRef62044 \" href=\"mobipreview.htm?28/29/29150\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Lack of edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similar considerations apply to hypokalemia. The potassium-wasting effect of excess aldosterone is counterbalanced by the potassium-retaining effect of hypokalemia itself. As a result, the plasma potassium concentration stabilizes at a lower level but progressive hypokalemia does not occur unless some other factor is added, such as increased aldosterone production or the use of diuretic therapy. The mechanisms by which hypokalemia limits further potassium wasting are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of hypokalemia\", section on 'Increased urinary losses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With both sodium and potassium handling, a new steady state is established in which the extracellular fluid volume and plasma potassium concentration are stable, although respectively increased and decreased because of the initial effects of aldosterone. In the steady state, both urinary sodium and potassium excretion are roughly equal to dietary intake, similar to that in normal subjects. Similar principles apply to the administration of diuretics, as a new steady state is achieved within two to three weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lack of edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although aldosterone initially induces sodium and water retention, this is followed within a few days by a spontaneous diuresis (called",
"    <strong>",
"     aldosterone escape",
"    </strong>",
"    ) that returns excretion to the level of intake and partially lowers the extracellular fluid volume toward normal (",
"    <a class=\"graphic graphic_figure graphicRef62044 \" href=\"mobipreview.htm?28/29/29150\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This response is induced by the volume expansion, as escape typically occurs in humans after a weight gain of approximately 3 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms responsible for the escape phenomenon are incompletely understood, but at least three factors may be important: increased secretion of",
"    <strong>",
"     atrial natriuretic peptide",
"    </strong>",
"    (ANP) induced by the hypervolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/8\">",
"     8",
"    </a>",
"    ]; decreased abundance of the thiazide-sensitive Na-Cl cotransporter that mediates sodium reabsorption in the distal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/9\">",
"     9",
"    </a>",
"    ]; and",
"    <strong>",
"     pressure natriuresis",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. In contrast, there appears to be no change in the abundance of the aldosterone-sensitive collecting tubule sodium channel (ENaC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased ANP release from the atria precedes the natriuresis. However, blocking the action of ANP markedly attenuates the initial natriuresis and delays, but does not prevent, complete manifestation of the escape phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, ANP appears important but not necessary for prevention of progressive sodium retention.",
"   </p>",
"   <p>",
"    Pressure natriuresis refers to the phenomenon whereby increasing renal perfusion pressure (due in part to systemic hypertension) enhances sodium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/10\">",
"     10",
"    </a>",
"    ]. How this occurs is not clear, but elevated renal interstitial pressure may indirectly diminish sodium reabsorption in the medullary segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6744?source=see_link&amp;anchor=H6#H6\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\", section on 'Pressure natriuresis'",
"    </a>",
"    .) Aldosterone escape can be prevented if a suprarenal aortic clamp is used to maintain a constant renal arterial pressure (",
"    <a class=\"graphic graphic_figure graphicRef73932 \" href=\"mobipreview.htm?6/52/6991\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension and hypokalemia are the two major clinical findings in primary aldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The elevation in blood pressure is dependent upon the mild volume expansion that occurs, being prevented in animals and effectively treated in humans by dietary sodium restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Persistent hypervolemia also leads to an increase in systemic vascular resistance that helps to perpetuate the hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/12\">",
"     12",
"    </a>",
"    ]. How this occurs is not known, but enhanced release of an endogenous ouabain-like compound has been postulated to play an important role in many forms of salt-sensitive hypertension.",
"   </p>",
"   <p>",
"    In addition to promoting the development of hypertension, hypervolemia is responsible for another characteristic finding in primary aldosteronism: marked suppression of renin release, leading to a very low plasma renin activity and plasma renin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The finding of suppressed renin measurements is of diagnostic importance in distinguishing primary from secondary, hyperreninemic forms of hyperaldosteronism, as occurs with renovascular hypertension, coarctation of the aorta, renin-secreting neoplasms, or diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The blood pressure in primary aldosteronism is often substantially elevated. In one series, as an example, the mean blood pressure was",
"    <span class=\"nowrap\">",
"     184/112",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     161/105",
"    </span>",
"    mmHg in patients with an adrenal adenoma and hyperplasia, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/14\">",
"     14",
"    </a>",
"    ]. Despite these high blood pressure levels, malignant hypertension is a rare occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary aldosteronism may be associated with resistant hypertension, which is defined as failure to achieve goal blood pressure (BP) despite adherence to an appropriate three-drug regimen including a diuretic. In a review of 1616 patients with resistant hypertension, 11 percent fulfilled criteria for primary aldosteronism; hypokalemia was seen in only 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=see_link&amp;anchor=H14#H14\">",
"     \"Definition, risk factors, and evaluation of resistant hypertension\", section on 'Primary aldosteronism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, hypertension is absent in patients with primary aldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/17\">",
"     17",
"    </a>",
"    ]. In this setting, the blood pressure may become very low with relief of the aldosterone excess, suggesting that aldosterone excess produced the expected significant increase in blood pressure over baseline.",
"   </p>",
"   <p>",
"    Even serum aldosterone levels in the high-normal range may be associated with increased blood pressure. This was illustrated in a report from the Framingham Offspring study in which baseline serum aldosterone levels were obtained among 1688 initially nonhypertensive participants (mean blood pressures of",
"    <span class=\"nowrap\">",
"     121/75",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     117/71",
"    </span>",
"    mmHg for men and women, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/18\">",
"     18",
"    </a>",
"    ]. At follow-up at four years, an increase in blood pressure category or the development of hypertension had occurred in 34 and 15 percent of individuals, respectively. Compared with the lowest quartile of serum aldosterone (range of 2.0 to 7.0",
"    <span class=\"nowrap\">",
"     ng/dL),",
"    </span>",
"    the highest quartile (range of 14.0 to 60 and 72",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    was associated with an increased risk of elevated blood pressure (1.60, 95% CI 1.19-2.14) and hypertension (1.61, 95% CI 1.05-2.46).",
"   </p>",
"   <p>",
"    Although these results are intriguing, interpretation of serum aldosterone levels requires knowledge of the exact level of salt and potassium intake and plasma renin values. These parameters were not available in enrolled individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypokalemia: an inconsistent finding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia is present in many patients with primary aldosteronism who are on an adequate sodium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/3,4,14\">",
"     3,4,14",
"    </a>",
"    ]. Two factors contribute to the urinary potassium wasting in this setting: the hypersecretion of aldosterone, which directly promotes potassium secretion in the cortical collecting tubule, and adequate delivery of sodium and water to the distal secretory site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/19\">",
"     19",
"    </a>",
"    ]. As an example, increasing sodium intake and, therefore, distal delivery will exacerbate the hypokalemia in this setting, since aldosterone secretion will not be appropriately suppressed by the volume expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the plasma potassium tends to be relatively stable at least over the short-term since the potassium-wasting effect of excess aldosterone is counterbalanced by the potassium-retaining effect of hypokalemia itself. Progressive hypokalemia does not occur unless some other factor is added, such as increased aldosterone production or the use of diuretic therapy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'The steady state'",
"    </a>",
"    above.) The mechanisms by which hypokalemia limits further potassium wasting are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of hypokalemia\", section on 'Increased urinary losses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with primary aldosteronism due to an adrenal adenoma and more commonly those with adrenal hyperplasia are",
"    <strong>",
"     not hypokalemic",
"    </strong>",
"    at presentation for reasons that are not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/3,4,16,21-23\">",
"     3,4,16,21-23",
"    </a>",
"    ]. With increasing use of the plasma aldosterone to plasma renin activity ratio as a case detection test from primary aldosteronism in hypertensive patients, more normokalemic patients are being identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/3,4,16,21-23\">",
"     3,4,16,21-23",
"    </a>",
"    ]. In a multicenter review using this approach, approximately 60 percent of patients with primary aldosteronism were not hypokalemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue has also been addressed in a number of rare hereditary disorders such as glucocorticoid-remediable aldosteronism (GRA, in which normal levels of ACTH are responsible for excess release of aldosterone) and Liddle's syndrome (in which there is a gain-of-function mutation in the collecting tubule sodium channel gene). In both of these disorders, many affected family members have hypertension but a normal or near-normal plasma potassium concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Liddle's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is estimated that more than 50 percent of patients with GRA have a normal plasma potassium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/24\">",
"     24",
"    </a>",
"    ]. Some studies suggest that the rate of normokalemia is even higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/25\">",
"     25",
"    </a>",
"    ]. However, there are two observations that suggest that total aldosterone exposure may be diminished in GRA; if so, then the frequent presence of normokalemia may not be applicable to other forms of primary aldosteronism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldosterone release in GRA is primarily under the influence of ACTH. With the normal circadian rhythm of ACTH release, aldosterone secretion should be above normal for only part of the day (ie, diurnal primary aldosteronism).",
"     </li>",
"     <li>",
"      Aldosterone synthesis in GRA primarily occurs in the zona fasciculata rather than the normal site, the zona glomerulosa. This may explain why dietary potassium does not induce the expected increase in aldosterone release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fall in the plasma potassium concentration that is often seen in primary aldosteronism is accompanied by metabolic alkalosis. This disorder is largely due to increased urinary hydrogen excretion mediated both by hypokalemia and by the direct stimulatory effect of aldosterone on distal acidification. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mild hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The persistent mild volume expansion resets the osmostat regulating antidiuretic hormone release and thirst upward by several",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, patients with primary aldosteronism usually have a stable plasma sodium concentration between 143 and 147",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypomagnesemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild",
"    hypomagnesemia due to urinary magnesium wasting also may occur in patients with persistent mineralocorticoid excess. How this occurs is incompletely understood. The ascending limb of the loop of Henle, as an example, is the primary site of tubular magnesium reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/27\">",
"     27",
"    </a>",
"    ]; inhibition of sodium transport in this segment during aldosterone escape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/6\">",
"     6",
"    </a>",
"    ] may be associated with a parallel decline in magnesium reabsorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other renal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone may raise the glomerular filtration rate (GFR) and renal perfusion pressure independent of systemic hypertension. In addition, increased urinary albumin excretion is common. These changes appear to be largely reversible with treatment as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 25 patients with primary aldosteronism, the GFR and effective renal plasma flow decreased six months after surgery for removal of adrenal adenoma, but did not change after blood pressure control in the comparison group with essential hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, hyperaldosteronism was associated with tubular dysfunction as assessed with urinary beta-2 microglobulin excretion, which improved six months after surgery. These changes cannot be explained by reductions in blood pressure alone, since the patients with adrenal adenoma and essential hypertension had similar blood pressure at baseline and blood pressure control at six months.",
"     </li>",
"     <li>",
"      Similar findings were seen in a second series of 50 patients with primary aldosteronism treated with adrenalectomy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      , and 100 patients with essential hypertension started on antihypertensive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/29\">",
"       29",
"      </a>",
"      ]. At baseline, the GFR and albumin excretion were higher in the patients with primary aldosteronism. In the first six months of follow-up, the reductions in GFR and albuminuria were significantly greater in the patients with primary aldosteronism who also were more likely to have restoration of normal albumin excretion. Blood pressure control was similar in the two groups.",
"     </li>",
"     <li>",
"      In a third report of 408 patients with primary aldosteronism (PA) and a control group of 408 patients with essential hypertension, more patients in the PA group had a serum creatinine concentration above 1.25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      controls (29 versus 10 percent in the PA and control groups, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/30\">",
"       30",
"      </a>",
"      ]. Age, male sex, low potassium, and high serum aldosterone concentrations were independent predictors of a lower GFR. In the PA group, adrenalectomy increased the serum creatinine and decreased the mean GFR from 71 to 64",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      resulted in a similar decline in GFR. Thus, surgical cure or mineralocorticoid receptor blockage reverse the hyperfiltration state and unmask the underlying renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness can occur in patients with primary aldosteronism. It is primarily due to hypokalemia and is not typically prominent unless the plasma potassium concentration is below 2.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link&amp;anchor=H3819896#H3819896\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Severe muscle weakness or rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with primary aldosteronism, when matched for age, blood pressure, and the duration of hypertension, have greater left ventricular mass measurements when compared to patients with other types of hypertension, including essential hypertension, pheochromocytoma, and Cushing's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Dietary salt may affect the impact of primary aldosteronism on cardiac damage. In a case-control study of 21 patients with primary aldosteronism and 21 control patients with essential hypertension, 24-hour urinary sodium excretion was an independent predictor for left ventricular wall thickness and mass in patients with primary aldosteronism, but not essential hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/34\">",
"     34",
"    </a>",
"    ]. Although data are limited, dietary salt restriction may help reduce cardiovascular risk in these patients.",
"   </p>",
"   <p>",
"    The risk of cardiovascular disease may also be increased as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study compared 124 patients with primary aldosteronism to 465 patients with apparent essential hypertension who were matched for age, gender, and blood pressure (mean",
"      <span class=\"nowrap\">",
"       175/107",
"      </span>",
"      mmHg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/35\">",
"       35",
"      </a>",
"      ]. The patients with primary aldosteronism had significantly higher rates of prior stroke (12.9 versus 3.4 percent in those with essential hypertension), nonfatal myocardial infarction (4.0 versus 0.6 percent), and atrial fibrillation (7.3 versus 0.6 percent). The rate of cardiovascular complications appeared to be similar in those with an adrenal adenoma and adrenal hyperplasia, but a rigorous distinction between these two subtypes was not pursued.",
"     </li>",
"     <li>",
"      Similar findings were noted in a prospective study that compared 54 patients with primary hyperaldosteronism who were treated with either surgical resection of an adrenal adenoma or the mineralocorticoid receptor antagonist",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      to a control group with essential hypertension, matched for age, gender, body mass index, and duration of hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/36\">",
"       36",
"      </a>",
"      ]. Prior to treatment, the prevalence of cardiovascular events was greater in patients with primary hyperaldosteronism than in patients with essential hypertension (odds ratio 4.6, 95% CI 2.4-9.0).",
"      <br/>",
"      <br/>",
"      However, the excess cardiovascular risk was no longer present after appropriate treatment of the mineralocorticoid excess. During a mean follow-up of 7.4 years after treatment, a similar proportion of patients in each group (18.5 and 17.6 percent, respectively) reached the primary outcome, which was a composite cardiovascular end point of myocardial infarction, stroke, revascularization procedure, or sustained arrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional evidence for the adverse cardiovascular effects of excess aldosterone comes from randomized controlled trials that have demonstrated improved survival with the mineralocorticoid receptor antagonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (in patients with advanced heart failure) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    (in patients with left ventricular dysfunction after a myocardial infarction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations are consistent with animal and human studies showing that hyperaldosteronism exerts deleterious cardiovascular effects independent of the plasma potassium concentration. These effects may be mediated at least in part by mineralocorticoid receptors in the heart and blood vessels (including coronary artery and aorta) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Activation of the mineralocorticoid receptor may act in part by impairing endothelial function, an effect that may be mediated by reduced glucose 6-phosphate dehydrogenase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/42\">",
"     42",
"    </a>",
"    ]. These effects can be largely or completely abolished by the administration of a mineralocorticoid receptor antagonist or by reducing plasma aldosterone concentrations by adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37911/abstract/40,42\">",
"     40,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia. The most common subtypes are aldosterone-producing adenoma and bilateral idiopathic hyperaldosteronism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary aldosteronism may be associated with resistant hypertension, which is defined as failure to achieve goal blood pressure (BP) despite adherence to an appropriate three-drug regimen including a diuretic. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although hypokalemia is considered to be a \"classic\" sign of primary aldosteronism, some patients with primary aldosteronism due to an adrenal adenoma and more commonly those with adrenal hyperplasia are not hypokalemic. With increasing use of the plasma aldosterone to plasma renin activity ratio to screen hypertensive patients for primary aldosteronism, more non-hypokalemic patients are being identified. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypokalemia: an inconsistent finding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aldosterone may raise the glomerular filtration rate (GFR) and renal perfusion pressure independent of systemic hypertension. In addition, increased urinary albumin excretion is common. These changes appear to be largely reversible with treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other renal effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with primary aldosteronism, when matched for age, blood pressure, and the duration of hypertension, have a greater risk of cardiovascular disease when compared to patients with other types of hypertension, including essential hypertension, pheochromocytoma, and Cushing's syndrome. The excess cardiovascular risk resolves after appropriate treatment of the mineralocorticoid excess. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardiovascular risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/1\">",
"      CONN JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med 1956; 97:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/2\">",
"      Bravo EL, Tarazi RC, Dustan HP, et al. The changing clinical spectrum of primary aldosteronism. Am J Med 1983; 74:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/3\">",
"      Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/4\">",
"      Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/5\">",
"      AUGUST JT, NELSON DH, THORN GW. Response of normal subjects to large amounts of aldosterone. J Clin Invest 1958; 37:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/6\">",
"      Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/7\">",
"      Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone \"escape\". Hypertension 1984; 6:I183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/8\">",
"      Yokota N, Bruneau BG, Kuroski de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994; 94:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/9\">",
"      Wang XY, Masilamani S, Nielsen J, et al. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 2001; 108:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/10\">",
"      Guyton AC. Blood pressure control--special role of the kidneys and body fluids. Science 1991; 252:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/11\">",
"      Kinoshita Y, Knox FG. Role of prostaglandins in proximal tubule sodium reabsorption: response to elevated renal interstitial hydrostatic pressure. Circ Res 1989; 64:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/12\">",
"      Clore J, Schoolwerth A, Watlington CO. When is cortisol a mineralocorticoid? Kidney Int 1992; 42:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/13\">",
"      Pedrinelli R, Bruschi G, Graziadei L, et al. Dietary sodium change in primary aldosteronism. Atrial natriuretic factor, hormonal, and vascular responses. Hypertension 1988; 12:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/14\">",
"      Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/15\">",
"      Zarifis J, Lip GY, Leatherdale B, Beevers G. Malignant hypertension in association with primary aldosteronism. Blood Press 1996; 5:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/16\">",
"      Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/17\">",
"      Vantyghem MC, Ronci N, Provost F, et al. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 1999; 141:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/18\">",
"      Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/19\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/20\">",
"      George JM, Wright L, Bell NH, Bartter FC. The syndrome of primary aldosteronism. Am J Med 1970; 48:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/21\">",
"      Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/22\">",
"      Fraser R, Murray GD, Connell JM. Conn's syndrome: no longer a needle in a haystack? Clin Endocrinol (Oxf) 1998; 49:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/23\">",
"      Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/24\">",
"      Litchfield WR, Coolidge C, Silva P, et al. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/25\">",
"      Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/26\">",
"      Gregoire JR. Adjustment of the osmostat in primary aldosteronism. Mayo Clin Proc 1994; 69:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/27\">",
"      Quamme GA. Control of magnesium transport in the thick ascending limb. Am J Physiol 1989; 256:F197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/28\">",
"      Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/29\">",
"      Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/30\">",
"      Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/31\">",
"      Shigematsu Y, Hamada M, Okayama H, et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/32\">",
"      Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/33\">",
"      Yoshihara F, Nishikimi T, Yoshitomi Y, et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens 1996; 9:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/34\">",
"      Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab 2011; 96:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/35\">",
"      Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/36\">",
"      Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/37\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/38\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/39\">",
"      Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/40\">",
"      Young WF Jr. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology 2003; 144:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/41\">",
"      Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37911/abstract/42\">",
"      Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13:189.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 140 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37911=[""].join("\n");
var outline_f37_1_37911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The steady state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lack of edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypokalemia: an inconsistent finding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mild hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other renal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/140|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/29/29150\" title=\"figure 2\">",
"      Resumption of the steady state in primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/52/6991\" title=\"figure 3\">",
"      Aldosterone escape II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37912="Temporal artery biopsy technique";
var content_f37_1_37912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Temporal artery biopsy technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Palma Shaw, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37912/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/1/37912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17025497\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy is the primary modality for establishing a diagnosis of giant cell (temporal) arteritis. Giant cell arteritis is a chronic vasculitis affecting medium and large diameter arteries, predominantly in older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The aortic arch vessels and branches, and particularly branches of the external carotid artery, are most prominently affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinical manifestations result from inflammation of the affected arteries or from their gradual occlusion leading to signs of arterial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technical aspects of arterial biopsy by which to confirm a diagnosis of giant cell arteritis are reviewed here. The pathogenesis, clinical manifestations, diagnostic evaluation, and treatment of giant cell arteritis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=see_link\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17025505\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy, which identifies the characteristic histopathology, remains the primary modality to diagnose giant cell (temporal) arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Other modalities used in the diagnosis of giant cell arteritis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The operating surgeon should be aware that the clinical manifestations of giant cell arteritis may overlap with those of polymyalgia rheumatica and both disease processes occur in similar patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/3\">",
"     3",
"    </a>",
"    ]. If there is any question regarding the need for biopsy, the operating surgeon should consult the referring physician. The clinical manifestations of giant cell (temporal) arteritis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Temporal artery biopsy is generally a straightforward procedure typically performed using local anesthetic with few complications. As such, there are no absolute contraindications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315277\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID THERAPY AND TIMING OF BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy should be performed as soon as feasible after referral for biopsy. Ideally, the biopsy is performed prior to the initiation of glucocorticoids, but sometimes this is not possible. The patient&rsquo;s primary physician or rheumatologist may have already initiated medical therapy, particularly in those with vascular complications (eg, visual loss) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Under this circumstance, temporal artery biopsy should ideally be obtained within a few of days of the initiation of glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/9\">",
"     9",
"    </a>",
"    ]. The effect of glucocorticoids on the histologic findings in the temporal artery is variable. However, in a case series of 535 patients, a similar rate of positive biopsy was found in those who had been treated with glucocorticoids (127 of 445 patients treated &le;14 days, 32 of 445 treated &gt;14 days), and those who had not been treated (n = 286) at 31 and 35 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On occasion, the patient may present for temporal artery biopsy after a more prolonged course of therapy. Some surgeons have suggested that temporal artery biopsy should not be performed if the patient has been treated with glucocorticoids for a prolonged period, since the likelihood of a positive biopsy is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/11\">",
"     11",
"    </a>",
"    ]. However, resolution of the inflammatory infiltrate in giant cell arteritis is slow, and the effect of glucocorticoid therapy on the histologic findings of temporal artery biopsy is variable, retrospective reviews have found that a diagnosis of arteritis can be made weeks, or less commonly, even months following treatment with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. Thus, when giant cell arteritis is strongly suspected, we perform temporal artery biopsy up to four weeks after glucocorticoid therapy has been initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17025512\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the course of the external carotid artery and its branches (superficial temporal artery, facial artery, occipital artery) and anatomic relationships to other structures are important for performing a safe arterial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315396\">",
"    <span class=\"h2\">",
"     Superficial temporal artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial temporal artery is a branch of the external carotid artery (ECA) (",
"    <a class=\"graphic graphic_figure graphicRef50495 \" href=\"mobipreview.htm?31/61/32728\">",
"     figure 1",
"    </a>",
"    ). The ECA has multiple branches that supply the face and scalp including (caudal to cranial) the superior thyroid, lingual, facial, ascending pharyngeal, occipital, posterior auricular, maxillary, and superficial temporal arteries.",
"   </p>",
"   <p>",
"    The superficial temporal artery arises posterior to the ramus of the mandible within the parotid gland and ascends anterior to the ear after giving off the transverse facial artery, then it courses superiorly over the zygoma dividing into frontal and parietal branches (",
"    <a class=\"graphic graphic_figure graphicRef82875 \" href=\"mobipreview.htm?40/50/41762\">",
"     figure 2",
"    </a>",
"    ). As it courses over the zygomatic process, it pierces and ascends beneath the superficial temporal fascia. Immediately beneath the superficial temporal fascia is a loosely adherent subdermal fatty layer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/15\">",
"     15",
"    </a>",
"    ]. The superficial temporal vein rarely accompanies the artery and tends to be located above the superficial temporal fascia (",
"    <a class=\"graphic graphic_figure graphicRef82876 \" href=\"mobipreview.htm?38/36/39490\">",
"     figure 3",
"    </a>",
"    ). The superficial temporal artery is accompanied by the auriculotemporal nerve, a branch of the mandibular nerve, on rare occasions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539631194\">",
"    <span class=\"h2\">",
"     Other cranial arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The facial artery provides the major arterial supply to the superficial face. It is a branch of the external carotid artery and courses along the inferior margin of the mandible (",
"    <a class=\"graphic graphic_figure graphicRef82875 \" href=\"mobipreview.htm?40/50/41762\">",
"     figure 2",
"    </a>",
"    ). The facial nerve accompanies the artery. The facial artery gives off multiple branches including the inferior labial, superior labial, and lateral nasal arteries, terminating as the angular artery.",
"   </p>",
"   <p>",
"    The occipital artery branches from the external carotid artery at the angle of the mandible. It passes medial to the posterior belly of the digastric muscle and mastoid process accompanied closely by the occipital nerve. The occipital nerve enters the subcuticular tissue below the external protuberance of the occiput, and shortly thereafter crosses the occipital artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17025519\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315417\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the majority of temporal artery biopsies can be performed using local anesthetic, the patient can remain on a clear liquid diet. In the rare event that sedation or general anesthesia is needed, any dietary restriction is dictated by the facility&rsquo;s anesthesia protocol. (See",
"    <a class=\"local\" href=\"#H1318148\">",
"     'Anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315339\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under most circumstances, the patient should be instructed to continue their current medications, particularly antihypertensive medications. Although the risk of bleeding is slightly increased in patients taking anticoagulant or antiplatelet medications, the time needed to discontinue, reverse, or bridge these medications and the risk of adverse events due to their cessation far outweigh the small risk of bleeding associated with the biopsy procedure. The use of local anesthetic with epinephrine reduces the potential for small vessel oozing. If bleeding does occur during the biopsy procedure, it can be controlled with direct pressure, sutures, electrocautery, or topical hemostatic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319170\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy is a clean, superficial, dermatologic procedure with a low incidence of surgical site infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/19\">",
"     19",
"    </a>",
"    ]. As such, antibiotic prophylaxis is generally not necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315297\">",
"    <span class=\"h1\">",
"     BIOPSY PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy involves removal of a segment (at least 2 cm of in vivo length) of the superficial temporal artery. Unlike other types of biopsies, in which a small sample of tissue is taken relative to the size of the organ (eg, liver biopsy), the temporal artery is excised in total with its transected proximal and distal ends ligated. Of the arteries potentially affected by giant cell arteritis, the temporal artery is the most easily accessible, and excising the vessel has minimal sequelae.",
"   </p>",
"   <p>",
"    Temporal artery biopsy is most typically performed in an outpatient setting (ambulatory surgery or office-based), usually in a minor procedure suite. The physician performing the surgery may be an ophthalmologist, neurosurgeon, general surgeon, vascular surgeon, or other surgical specialist.",
"   </p>",
"   <p>",
"    Informed consent is obtained and the surgeon should clearly explain the reason for the biopsy, including the potential complications of the procedure (see",
"    <a class=\"local\" href=\"#H17025556\">",
"     'Complications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The possibility that a negative biopsy may be obtained, and its implications should also be explained. Repeat biopsy of the opposite side may be needed if initial unilateral biopsy was chosen. (See",
"    <a class=\"local\" href=\"#H345690677\">",
"     'Unilateral versus bilateral biopsy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1315605\">",
"     'Need for repeat biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315425\">",
"    <span class=\"h2\">",
"     Site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial temporal artery is the most common artery sampled to establish a diagnosis of giant cell (temporal) arteritis. Biopsy of alternative arterial sites may be needed if the diagnosis remains in question in spite of negative temporal artery biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1292802829\">",
"    <span class=\"h3\">",
"     Superficial temporal artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial temporal arteries are palpated bilaterally to assess for patency and clinical signs of arteritis. A pulse is usually easily detected at the superior margin of the tragus of the ear, but it may be difficult to appreciate due to vessel thickening or the vessel may be thrombosed. If the vessel is not palpable, a hand-held Doppler can be used to help localize it. After identification of the temporal artery, it is marked with an indelible surgical marker with cross hatches where it is abnormal (nodular, tender). Although biopsy of a patent vessel may be preferred, histopathologic changes associated with giant cell arteritis can be identified in a thrombosed artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, if a patent temporal artery is not found, biopsy of a thrombosed artery may be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345690677\">",
"    <span class=\"h4\">",
"     Unilateral versus bilateral biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians prefer unilateral biopsy in all patients followed by biopsy of the contralateral temporal artery if the initial biopsy is negative. Others prefer bilateral temporal artery biopsy on all patients. There are no high quality data to support one approach over the other. Based upon the findings in retrospective reviews, we perform unilateral temporal artery biopsy in those with clearly lateralizing symptoms (unilateral headache, unilateral visual disturbance) or signs (eg, unilateral inflamed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tender temporal artery). For those without lateralizing clinical features, we perform bilateral temporal artery biopsies rather than a &ldquo;blind&rdquo; unilateral biopsy given the low morbidity of the procedure, the gravity of the diagnosis, and also practical considerations. Physician and patient preference also play a role in making this decision.",
"   </p>",
"   <p>",
"    Unilateral temporal artery biopsy is frequently sufficient to establish the diagnosis of giant cell arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. However, unilateral biopsy is negative in up to 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/22-30\">",
"     22-30",
"    </a>",
"    ]. The left or right temporal artery is selected based upon the presence of lateralizing features including symptoms such as pain or visual disturbances, or signs such as temporal artery nodularity or tenderness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a retrospective review of 1113 patients, temporal artery biopsy was more likely to be positive in patients with jaw claudication plus new headache, scalp tenderness, or decreased vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/9\">",
"     9",
"    </a>",
"    ]. In another review of patients selected for unilateral biopsy, a positive biopsy was significantly more likely in patients with visual symptoms (OR 4.9, 95% CI 1.28-18.70), or an abnormal temporal artery on physical examination (OR 3.2, 95% CI 1.3-7.71) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of lateralizing symptoms or an inflamed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tender temporal artery on physical examination, a &ldquo;blind&rdquo; unilateral biopsy or bilateral biopsies can be performed. A negative history or physical examination is more likely if glucocorticoid therapy has been initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/9\">",
"     9",
"    </a>",
"    ]. For these patients, the history and physical findings prior to treatment may help guide site selection if unilateral biopsy is chosen. Consultation with the patient&rsquo;s primary provider or rheumatologist may be helpful.",
"   </p>",
"   <p>",
"    Studies of false-negative unilateral temporal artery biopsy suggested that performing bilateral temporal artery biopsies would increase the rate of positive biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In pathology reviews, between 3 and 25 percent of patients with a negative unilateral biopsy have a positive biopsy on the contralateral side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. Thus, some experts suggest that biopsy of the right and left temporal arteries should be performed simultaneously, rather than sequentially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. In a nonrandomized review of 908 specimens from 758 patients (300 simultaneous bilateral, 72 bilateral sequential in 36 patients, 536 unilateral), there were no differences in the results of histology regardless of whether the biopsies were obtained simultaneously or sequentially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/26\">",
"     26",
"    </a>",
"    ]. An identical diagnosis was found on both sides in 97 percent of patients. Given the low morbidity of the procedure, the gravity of the diagnosis, and practical considerations, such as not needing to return for a repeat biopsy, we advocate bilateral biopsy when lateralizing features are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315512\">",
"    <span class=\"h3\">",
"     Other biopsy sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although giant cell arteritis is often called \"temporal\" arteritis, the disease process is not limited to the temporal artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Other accessible vessels such as the facial or occipital arteries may be affected, and on occasion, these may be used as alternative biopsy sites. If the temporal arteries are not symptomatic and have no abnormalities on examination, but the facial or occipital arteries are symptomatic and abnormal on physical examination, then facial or occipital artery biopsy can be performed in a manner that is similar to temporal artery biopsy. Biopsy of these vessels may also be considered if bilateral temporal artery biopsy is negative and the diagnosis remains in question. (See",
"    <a class=\"local\" href=\"#H17025549\">",
"     'Alternative biopsy sites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1317745\">",
"    <span class=\"h2\">",
"     Materials and equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to performing the biopsy, all the necessary medications, instruments and other equipment should be collected in advance (",
"    <a class=\"graphic graphic_table graphicRef82862 \" href=\"mobipreview.htm?1/30/1517\">",
"     table 1",
"    </a>",
"    ). Electrocautery using an electrosurgical unit is not usually needed. If bleeding is encountered, a hand-held battery-powered electrocautery pen usually suffices. Overhead surgical lighting (permanent or portable) is essential. If bilateral temporal artery sites have been prepared, it is reasonable to use the same set of sterile instruments for both sides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1317721\">",
"    <span class=\"h2\">",
"     Patient positioning and skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should remove all jewelry, including any necklaces or earrings, and should disrobe above the waist. For women, the brassiere should also be removed to eliminate the potential for soilage. The patient is then positioned supine on a standard procedure table with the head placed on a pillow.",
"   </p>",
"   <p>",
"    For temporal artery biopsy, the patient&rsquo;s head is positioned facing away from the selected temporal artery site to anteriorly position the temporal artery. We prefer to prepare both temporal regions, in anticipation of the need to perform bilateral biopsies. Shaving a small area of hair from the temporal region is usually required to obtain sufficient exposure, and the patient&rsquo;s skin is prepared and drapes placed. Tenting the drapes so the patient&rsquo;s face is not completely covered is better tolerated by the patient. Specific skin preparation agents to prevent surgical site infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318148\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial biopsy is usually performed using only local anesthesia. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    cream can be applied to the skin for several minutes prior to skin preparation to decrease pain at the lidocaine infiltration site. If the patient is allergic to local anesthetics, total intravenous anesthesia is an alternative, typically administered by an anesthesiologist in an outpatient, ambulatory surgery setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For temporal artery biopsy, local anesthetic is injected into the skin and subcutaneous tissues over the planned arterial site after the region has been prepared and draped. If bilateral biopsies are performed, local anesthetic is administered just prior to the contralateral incision. We prefer to use a 1:1 mixture of 1%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine (1:200,000) and 0.5%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    with epinephrine (1:200,000) to provide a rapid onset of analgesia (within four to five minutes) and prolonged pain relief up to three hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318197\">",
"    <span class=\"h2\">",
"     Biopsy technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variability in the technique of temporal artery biopsy, particularly in the amount of temporal artery harvested, may contribute to the variable rates of positive biopsy results that are reported in retrospective reviews. Key points in performing temporal artery biopsy to improve yield and minimize complications include obtaining an appropriate length of vessel (at least 2 cm in vivo), including visibly abnormal or clinically affected (eg, tender) areas of the vessel, and avoiding nerves.",
"   </p>",
"   <p>",
"    The incision is made overlying the temporal artery at the previously marked skin site (see",
"    <a class=\"local\" href=\"#H1292802829\">",
"     'Superficial temporal artery'",
"    </a>",
"    above). The incision should be large enough to easily see at least 3 cm of the vessel, and although a horizontal or vertical incision can be made, a vertical incision (parallel to the vessel) facilitates the harvest of a longer segment of the artery. The dissection is carried through the subcutaneous fat parallel to the vessel with care not to injure the vessel; a self-retaining retractor can be placed (",
"    <a class=\"graphic graphic_figure graphicRef82877 \" href=\"mobipreview.htm?25/33/26133\">",
"     figure 4",
"    </a>",
"    ). As the incision is carried through the hairline, disrupting the hair follicles can be minimized by following the direction of the hair shafts to reduce the risk of incisional alopecia. Division of the overlying temporoparietal fascia exposes the superficial temporal artery. At least 3 cm of the artery should be exposed to achieve at least a 2 cm in vivo temporal artery specimen. The rationale for this length of artery is discussed below. (See",
"    <a class=\"local\" href=\"#H1318537\">",
"     'Specimen length'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The artery is ligated proximally and distally, or small hemostats are used to clamp the artery proximally and distally; the intervening segment of vessel is removed with tenotomy scissors. The arterial stumps are singly or doubly ligated with non-absorbable suture (eg, silk) (",
"    <a class=\"graphic graphic_figure graphicRef82877 \" href=\"mobipreview.htm?25/33/26133\">",
"     figure 4",
"    </a>",
"    ). Once hemostasis is obtained (pressure, electrocautery, topical agent), the wound is irrigated and closed with subcuticular sutures. We prefer to use 4-0, braided, absorbable suture in the subcutaneous tissue and 5-0 absorbable, monofilament suture in the skin. Adhesive skin strips and a nonadherent, absorbable dressing (eg, Telfa) are placed and covered with a transparent self-adhesive film dressing (eg, Tegaderm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318537\">",
"    <span class=\"h3\">",
"     Specimen length",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sufficient specimen length is important for an accurate diagnosis due to the segmental nature of the disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/23\">",
"     23",
"    </a>",
"    ]. Unfortunately, supporting data for the various opinions about optimal biopsy length are lacking. Based upon retrospective reviews and clinical experience, we suggest a minimum in vivo biopsy length of 2 cm. The greater the length of artery that can be taken, the greater the likelihood of a positive result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/32,37-39\">",
"     32,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 966 temporal artery biopsies obtained over five years at six hospitals, biopsies with a postfixation specimen length of &gt;0.7 cm had a significantly higher rate of positive results compared with shorter lengths (24.8 versus 12.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another review of 200 specimens, the average length that gave positive results was significantly longer than the length that gave normal results (10.6 versus 8.6 mm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of 47 biopsies found average lengths for positive and negative biopsies of 1.84 cm and 1.29 cm, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a series of 134 biopsies obtained over a 15-year period, biopsy samples that were positive had a mean length that was shorter than biopsy samples that were negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/29\">",
"       29",
"      </a>",
"      ]. In this study, longer biopsy samples were obtained, (unilateral biopsy: mean length 3.5 cm [range 0.5-12.5 cm]; bilateral biopsy: mean length 6.7 cm [range 1.5-17.5 cm]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the larger and more contemporary studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/37,40,41\">",
"     37,40,41",
"    </a>",
"    ], a specimen length of 1 to 2 cm may be sufficient. However, it is important to remember that some shrinkage with fixation will occur. One pathology study noted an average of 2.4 mm shrinkage in the length of the biopsy with fixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. On average, about 10 percent shrinkage can be expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/44\">",
"     44",
"    </a>",
"    ]. Given the need to account for shrinkage, we suggest the in vivo specimen length should be at least 2 cm. If the artery appears normal, a longer segment of the temporal artery should be obtained, provided doing so will not risk additional complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/32,45\">",
"     32,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17025556\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A ruler can be used to measure and document the length of artery, in vivo, prior to its removal. To achieve an adequate length of artery, the dissection may need to be extended superior to the bifurcation of the superficial temporal artery following the course of the frontal or parietal branch. Although the frontal branch is easier to expose, branch facial nerve injury may lead to eyebrow droop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This complication can be avoided by extending the biopsy toward the parietal branch instead when additional length is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17025549\">",
"    <span class=\"h2\">",
"     Alternative biopsy sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potentially affected arteries include the facial and occipital arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Biopsy of these vessels can be performed; however, each is accompanied by their respective nerves and the risk of nerve injury may outweigh the usefulness of obtaining a specimen from these sites. For the occipital artery, some suggest that the biopsy site should be between 1 and 3 cm above (cranially) and 4 to 5 cm lateral to the external occipital protuberance to avoid occipital nerve injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H539631194\">",
"     'Other cranial arteries'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H539631456\">",
"     'Nerve injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315527\">",
"    <span class=\"h2\">",
"     Specimen handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the arterial segment has been removed, it should be immediately placed into a clearly labelled specimen jar containing formalin for permanent section. In medical centers with appropriate experience, a portion of the specimen can be sent for frozen section to secure an immediate diagnosis. However, fixed, permanent sections should be obtained in all instances. The patient&rsquo;s primary physician or rheumatologist should be included in the report for notification of the results. The histologic findings of giant cell arteritis are described elsewhere (",
"    <a class=\"graphic graphic_picture graphicRef57876 \" href=\"mobipreview.htm?16/56/17289\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318135\">",
"    <span class=\"h1\">",
"     FOLLOW-UP INSTRUCTIONS AND CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the temporal artery biopsy procedure is completed and the dressings have been placed, the patient can return home as soon as they meet discharge criteria. For most patients, this is fairly immediate. The patient is instructed to maintain the dressing over the biopsy site(s) for 24 hours, after which the outer transparent film dressing can be removed. The adhesive strips on the skin should remain in place for several days and the patient is instructed to avoid the region when washing their hair.",
"   </p>",
"   <p>",
"    The patient should be informed that the sutures placed beneath the skin will be absorbed, and thus, do not require removal. The incision(s) may become itchy but the patient should avoid scratching the area. The patient should call the surgeon if there are any wound-related problems (bleeding, drainage) or other questions. Under most circumstances, the patient can expect to be notified of the pathology results within two to three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315605\">",
"    <span class=\"h1\">",
"     NEED FOR REPEAT BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal artery biopsy is negative in up to about 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/9,32,51\">",
"     9,32,51",
"    </a>",
"    ]. A ratio of positive to negative biopsies of 1:2 is typical of most series. (See",
"    <a class=\"local\" href=\"#H1315425\">",
"     'Site selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A negative temporal artery biopsy may indicate that the patient does not have giant cell arteritis, or that the patient has the disease but the sampled artery was not involved in the pathologic process. A variant of the disease spares the cranial arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If unilateral biopsy is negative, the patient&rsquo;s primary physician or rheumatologist may request a contralateral biopsy depending upon the initial presenting symptoms and response to glucocorticoid therapy. For patients with negative bilateral temporal artery biopsy, biopsy of alternative sites may be requested to establish a histologic diagnosis. (See",
"    <a class=\"local\" href=\"#H17025549\">",
"     'Alternative biopsy sites'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17025556\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of temporal artery biopsy are uncommon but may include bleeding (arterial or venous), surgical site infection, and nerve injury involving the auriculotemporal nerve, or branches of the facial nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315929\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sequelae of temporal artery biopsy is minor oozing from the wound; however, sudden, more significant bleeding can occur if a ligature dislodges from the cut end of the proximal temporal artery. The use of double ligation or, for larger vessels, suture ligation, rather than simple ligation may help avert this problem. Bleeding can usually be controlled with direct pressure, but, under rare circumstances, re-exploration of the wound may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539631456\">",
"    <span class=\"h2\">",
"     Nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for facial nerve injury is increased when temporal artery biopsy is carried over the frontal branch of the superficial temporal artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Injury to the facial nerve and complications such as eyebrow droop can be avoided by extending the biopsy towards the parietal branch if additional length is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37912/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1315396\">",
"     'Superficial temporal artery'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1318537\">",
"     'Specimen length'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The occipital nerve is easily injured below the occipital protuberance and injury can lead to upper neck or posterior cranial pain, or pain behind the eyes. Thus, occipital artery biopsy should be performed superior to the occipital protuberance. (See",
"    <a class=\"local\" href=\"#H539631194\">",
"     'Other cranial arteries'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1315512\">",
"     'Other biopsy sites'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=see_link\">",
"       \"Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1314797\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giant cell arteritis is a chronic vasculitis affecting medium and large arteries, predominantly in older individuals. The branches of the aortic arch are the most prominently affected. The clinical manifestations result from inflammation of the affected arteries or from their gradual occlusion leading to signs of arterial ischemia. (See",
"      <a class=\"local\" href=\"#H17025497\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Temporal artery biopsy remains the primary diagnostic modality to establish a diagnosis of giant cell arteritis. Temporal artery biopsy involves the removal of a segment of the superficial temporal artery for histologic examination. Although giant cell arteritis is often called \"temporal\" arteritis, the disease process is not limited to the temporal artery. Other accessible vessels such as the facial or occipital arteries may be affected, and on occasion, these may be used as alternative biopsy sites. (See",
"      <a class=\"local\" href=\"#H17025505\">",
"       'Indications for biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1315512\">",
"       'Other biopsy sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Temporal artery biopsy is typically performed in an outpatient setting using only local anesthesia. Fasting is not required and the patient can continue their normal medications. Although the risk of bleeding is slightly increased in patients taking anticoagulant or antiplatelet medications, the time needed to discontinue, reverse, or bridge these medications, and the risk of adverse events due to their cessation far outweighs the small risk of bleeding associated with the biopsy procedure. Antibiotic prophylaxis is generally",
"      <strong>",
"       not",
"      </strong>",
"      necessary for this clean procedure. (See",
"      <a class=\"local\" href=\"#H17025519\">",
"       'Patient preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some clinicians prefer unilateral biopsy in all patients followed by biopsy of the contralateral temporal artery if the initial biopsy is negative. Others prefer bilateral temporal artery biopsy on all patients. There are no high quality data to support one approach over the other. Physician and patient preference also play a role in making this decision. Our approach is as follows: (see",
"      <a class=\"local\" href=\"#H1315425\">",
"       'Site selection'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with lateralizing symptoms (unilateral headache, unilateral visual disturbance) or signs (eg, unilateral inflamed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tender temporal artery), we suggest unilateral temporal artery biopsy performed on the side of the",
"      <span class=\"nowrap\">",
"       symptoms/signs",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients without lateralizing symptoms or signs, we suggest bilateral temporal artery biopsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sufficient specimen length is important for an accurate diagnosis due to the segmental nature of the disease process. We suggest a minimum in vivo temporal artery biopsy length of 2 cm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The greater the length of artery that can be taken, the greater the likelihood of a positive result, particularly if the vessel is normal in appearance. Other key points in performing the biopsy procedure include biopsy of clinically affected areas of the vessel, and avoidance of local nerves. (See",
"      <a class=\"local\" href=\"#H1318197\">",
"       'Biopsy technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A negative temporal artery biopsy occurs in up to 50 percent of patients, and may indicate that the patient does not have giant cell arteritis, or that the patient has the disease but the sampled region was not involved in the pathologic process. If unilateral biopsy is negative, a contralateral biopsy may be needed depending upon the strength of the clinical scenario. For patients with negative bilateral temporal artery biopsies, biopsy of alternative sites can be performed if a histologic diagnosis is needed. (See",
"      <a class=\"local\" href=\"#H1315605\">",
"       'Need for repeat biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1315512\">",
"       'Other biopsy sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of temporal artery biopsy are uncommon; however, bleeding (arterial or venous), surgical site infection, and nerve injury can occur. Incisional alopecia can also occur, but can be avoided if the incision is made parallel to the plane of the hair shafts. (See",
"      <a class=\"local\" href=\"#H17025556\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1318197\">",
"       'Biopsy technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/1\">",
"      BIRKHEAD NC, WAGENER HP, SHICK RM. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J Am Med Assoc 1957; 163:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/2\">",
"      Horton BT, Magath TB, Brown GE. Undescribed form of arteritis of temporal vessels. Proc Staff Meet Mayo Clin 1932; 7:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/3\">",
"      Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/4\">",
"      Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978; 88:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/5\">",
"      HOLLENHORST RW, BROWN JR, WAGENER HP, SHICK RM. Neurologic aspects of temporal arteritis. Neurology 1960; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/6\">",
"      Meisner RJ, Labropoulos N, Gasparis AP, Tassiopoulos AK. How to diagnose giant cell arteritis. Int Angiol 2011; 30:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/7\">",
"      Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012; 41:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/8\">",
"      Dasgupta B, Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med 2010; 10:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/9\">",
"      Younge BR, Cook BE Jr, Bartley GB, et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc 2004; 79:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/10\">",
"      Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/11\">",
"      Narv&aacute;ez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007; 37:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/12\">",
"      Lee YC, Padera RF, Noss EH, et al. Clinical course and management of a consecutive series of patients with \"healed temporal arteritis\". J Rheumatol 2012; 39:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/13\">",
"      Allison MC, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis 1984; 43:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/14\">",
"      Evans JM, Batts KP, Hunder GG. Persistent giant cell arteritis despite corticosteroid treatment. Mayo Clin Proc 1994; 69:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/15\">",
"      Scott KR, Tse DT, Kronish JW. Temporal artery biopsy technique: a clinico-anatomical approach. Ophthalmic Surg 1991; 22:519.",
"     </a>",
"    </li>",
"    <li>",
"     Clinically Oriented Anatomy, 5th ed, Moore KL, Dalley AF.  (Eds),  p.947.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/17\">",
"      Shimizu S, Oka H, Osawa S, et al. Can proximity of the occipital artery to the greater occipital nerve act as a cause of idiopathic greater occipital neuralgia? An anatomical and histological evaluation of the artery-nerve relationship. Plast Reconstr Surg 2007; 119:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/18\">",
"      Schmidt D, Adelmann G. The course of the occipital artery--an anatomical investigation for biopsy in suspected vasculitis. Eur J Med Res 2001; 6:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/19\">",
"      Rossi AM, Mariwalla K. Prophylactic and empiric use of antibiotics in dermatologic surgery: a review of the literature and practical considerations. Dermatol Surg 2012; 38:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/20\">",
"      Gunawardena H, Kyle MV. Atypical presentations of giant cell arteritis - A district general hospital perspective. Rheumatology 2005; 44(Suppl 3):iii17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/21\">",
"      Mar&iacute; B, Monteagudo M, Bustamante E, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med 2009; 20:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/22\">",
"      Roth AM, Milsow L, Keltner JL. The ultimate diagnoses of patients undergoing temporal artery biopsies. Arch Ophthalmol 1984; 102:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/23\">",
"      Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Mayo Clin Proc 1976; 51:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/24\">",
"      Sorensen S, Lorenzen I. Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. Acta Med Scand 1977; 201:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/25\">",
"      Hall S, Hunder GG. Is temporal artery biopsy prudent? Mayo Clin Proc 1984; 59:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/26\">",
"      Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 1999; 128:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/27\">",
"      Pless M, Rizzo JF 3rd, Lamkin JC, Lessell S. Concordance of bilateral temporal artery biopsy in giant cell arteritis. J Neuroophthalmol 2000; 20:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/28\">",
"      Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol 2009; 36:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/29\">",
"      Hall S, Persellin S, Lie JT, et al. The therapeutic impact of temporal artery biopsy. Lancet 1983; 2:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/30\">",
"      Calamia, KT, Matteson, EL, Mazlumzadeh, M, et al. Trends in the use of temporal artery biopsy for the diagnosis of giant cell arteritis (GCA): Experience in 2539 patients at 3 centers over 11 years (abstract). Arthritis Rheum 2005; 52 Suppl:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/31\">",
"      Kent, RB, Thomas, L. Temporal artery biopsy. Am Surg 1989; 56:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/32\">",
"      Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001; 30:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/33\">",
"      Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/34\">",
"      Tat&ograve; F, Hoffmann U. Giant cell arteritis: a systemic vascular disease. Vasc Med 2008; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/35\">",
"      Czihal M, Brendel T, Seibold C, et al. Listen to the axillary artery: diagnosis of occult giant cell arteritis. J Clin Rheumatol 2011; 17:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/36\">",
"      Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011; 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/37\">",
"      Ypsilantis E, Courtney ED, Chopra N, et al. Importance of specimen length during temporal artery biopsy. Br J Surg 2011; 98:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/38\">",
"      Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol 2009; 27:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/39\">",
"      Taylor-Gjevre R, Vo M, Shukla D, Resch L. Temporal artery biopsy for giant cell arteritis. J Rheumatol 2005; 32:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/40\">",
"      Sudlow C. Diagnosing and managing polymyalgia rheumatica and temporal arteritis. Sensitivity of temporal artery biopsy varies with biopsy length and sectioning strategy. BMJ 1997; 315:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/41\">",
"      Goslin BJ, Chung MH. Temporal artery biopsy as a means of diagnosing giant cell arteritis: is there over-utilization? Am Surg 2011; 77:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/42\">",
"      Danesh-Meyer HV, Savino PJ, Bilyk JR, et al. Shrinkage: fact or fiction? Arch Ophthalmol 2001; 119:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/43\">",
"      Caroe A. Temporal artery biopsy to diagnose temporal arteritis. JAMA 1998; 280:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/44\">",
"      Gordon LK, Levin LA. Visual loss in giant cell arteritis. JAMA 1998; 280:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/45\">",
"      Cetinkaya A, Kersten RC, Brannan PA, et al. Intraoperative predictability of temporal artery biopsy results. Ophthal Plast Reconstr Surg 2008; 24:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/46\">",
"      Albertini JG, Ramsey ML, Marks VJ. Temporal artery biopsy in a dermatologic surgery practice. Dermatol Surg 1999; 25:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/47\">",
"      Rison RA. Branch facial nerve trauma after superficial temporal artery biopsy: a case report. J Med Case Rep 2011; 5:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/48\">",
"      Yoon MK, Horton JC, McCulley TJ. Facial nerve injury: a complication of superficial temporal artery biopsy. Am J Ophthalmol 2011; 152:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/49\">",
"      Achkar AA, Lie JT, Gabriel SE, Hunder GG. Giant cell arteritis involving the facial artery. J Rheumatol 1995; 22:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/50\">",
"      Kattah JC, Cupps T, Manz HJ, et al. Occipital artery biopsy: a diagnostic alternative in giant cell arteritis. Neurology 1991; 41:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/51\">",
"      Lie JT. When is arteritis of the temporal arteries not temporal arteritis? J Rheumatol 1994; 21:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37912/abstract/52\">",
"      Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999; 42:311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15206 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37912=[""].join("\n");
var outline_f37_1_37912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1314797\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17025497\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17025505\">",
"      INDICATIONS FOR BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1315277\">",
"      GLUCOCORTICOID THERAPY AND TIMING OF BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17025512\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1315396\">",
"      Superficial temporal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H539631194\">",
"      Other cranial arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17025519\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1315417\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1315339\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1319170\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1315297\">",
"      BIOPSY PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1315425\">",
"      Site selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1292802829\">",
"      - Superficial temporal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H345690677\">",
"      Unilateral versus bilateral biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1315512\">",
"      - Other biopsy sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1317745\">",
"      Materials and equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1317721\">",
"      Patient positioning and skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1318148\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1318197\">",
"      Biopsy technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1318537\">",
"      - Specimen length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17025549\">",
"      Alternative biopsy sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1315527\">",
"      Specimen handling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1318135\">",
"      FOLLOW-UP INSTRUCTIONS AND CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1315605\">",
"      NEED FOR REPEAT BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17025556\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1315929\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H539631456\">",
"      Nerve injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1314797\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15206|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/61/32728\" title=\"figure 1\">",
"      External carotid artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/50/41762\" title=\"figure 2\">",
"      Course of the superficial temporal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/36/39490\" title=\"figure 3\">",
"      Superfical temporal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/33/26133\" title=\"figure 4\">",
"      Temporal artery biopsy technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15206|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/56/17289\" title=\"picture 1\">",
"      Giant cell arteritis light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/30/1517\" title=\"table 1\">",
"      Suggested equipment for temporal artery biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=related_link\">",
"      Pathogenesis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37913="Decontamination of poisoned children";
var content_f37_1_37913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Decontamination of poisoned children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Larissa I Velez, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Collin S Goto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     J Greene Shepherd, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37913/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/1/37913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, in 2008, there were approximately 2.4 million toxic exposures reported to the American Association of Poison Control Centers&rsquo; National Poison Data System (NPDS) by 61 participating poison centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/1\">",
"     1",
"    </a>",
"    ]. Two-thirds of these exposures occurred in children younger than 20 years of age, and one-half of those were in children younger than six years. Every physician who cares for children should be familiar with the evaluation and management of poisoning.",
"   </p>",
"   <p>",
"    Management of the poisoned child begins with stabilization of the airway, breathing, and circulation. Once stabilization has occurred, the clinician must perform a thorough evaluation to identify the agent(s) involved and to assess the severity of the exposure. The possibility of concomitant trauma or illness must be recognized and addressed prior to initiation of decontamination.",
"   </p>",
"   <p>",
"    Decontamination refers to the techniques used to prevent the absorption of the toxic substance by the body. Decontamination methods vary according to the route of exposure (oral, inhalation, dermal, ocular), the time elapsed since the exposure, and the expected toxicity of the exposure. Regardless of the method employed, efficacy decreases with the length of delay between exposure and treatment. The benefit versus the risk of decontamination must be considered for each child; decontamination is",
"    <strong>",
"     not",
"    </strong>",
"    always warranted and may be contraindicated.",
"   </p>",
"   <p>",
"    Decontamination procedures for the poisoned child are reviewed here. Enhanced elimination of toxins and a general approach to the poisoned child are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific management of common ingestions (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , and iron) is reviewed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ORAL EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral ingestions account for 76 percent of reported exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ]. The spectrum of oral exposures in children ranges from the small, unintentional, minimally toxic ingestion to the large, intentional, potentially lethal overdose. The severity of the ingestion depends upon the type and number of substances ingested and the chronicity of the ingestion. The agents most commonly ingested by children younger than six years old are listed in table 1 (",
"    <a class=\"graphic graphic_table graphicRef55650 \" href=\"mobipreview.htm?17/62/18411\">",
"     table 1",
"    </a>",
"    ); the agents involved in fatal poisoning of children younger than six years old are listed in table 2 (",
"    <a class=\"graphic graphic_table graphicRef61883 \" href=\"mobipreview.htm?4/18/4395\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    is the primary means of gastrointestinal (GI) decontamination after ingestion of a toxic substance. However, some toxic agents do not bind well to activated charcoal (",
"    <a class=\"graphic graphic_table graphicRef77553 \" href=\"mobipreview.htm?4/37/4700\">",
"     table 3",
"    </a>",
"    ). Other modalities (eg, syrup of ipecac, gastric lavage, whole bowel irrigation, and endoscopic or surgical removal of the ingested poison) are less effective. Cathartics and dilution can be used in conjunction with other modalities but are not effective methods of GI decontamination when used alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032467\">",
"    <span class=\"h2\">",
"     Activated charcoal",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    has become the",
"    <strong>",
"     preferred method",
"    </strong>",
"    of GI decontamination in children. During 2008, 3.8 percent of the patients received activated charcoal for decontamination compared with 4 percent of exposures in 1983 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    is an insoluble, nonabsorbable, fine carbon powder made from the burning and crushing of wood, coconut shells, coal, petroleum products, or peat that is then heated with steam, air, or carbon dioxide in the \"activation\" process, which adds surface area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4\">",
"     4",
"    </a>",
"    ]. Activated charcoal has an extensive network of interconnecting pores that bind (adsorb) and trap chemicals within minutes of contact, thereby preventing their absorption and toxicity. Activated charcoals in current use have a binding surface area of 950 to 2000 m2 per gram and can absorb between a few mg and 1 g of intoxicant per gram of activated charcoal. The amount of drug bound by charcoal is dependent upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristics of the ingested substance. Most xenobiotics bind well to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      with the exception of small, highly ionized chemicals such as metals, electrolytes, acids, and alkali (",
"      <a class=\"graphic graphic_table graphicRef77553 \" href=\"mobipreview.htm?4/37/4700\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The surface area of the specific",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      preparation employed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relative amounts of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      and the intoxicant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More than 90 percent of an intoxicant generally is adsorbed when the ratio of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    to intoxicant is 10:1 or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4\">",
"     4",
"    </a>",
"    ]. Larger doses of activated charcoal, either as single or multiple doses, are more effective at preventing drug absorption by mass action, even when the activated charcoal:intoxicant ratio is maintained constant.",
"   </p>",
"   <p>",
"    Multiple doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    are used to enhance preabsorptive and postabsorptive elimination by exploiting the effects of certain drugs that slow gastrointestinal motility (eg, anticholinergics or sustained released drugs), interrupting enterohepatic circulation, or \"gastrointestinal dialysis\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032536\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    is 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of body weight (maximum 50 to 60 gm), usually without",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    . It is prepared in a slurry with water or other liquid and can be given orally or via a nasogastric tube after proper placement is confirmed. Small amounts of chocolate milk, fruit syrup, or cola drinks can be added to make the charcoal more palatable without reducing its efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Sorbitol does not aid in preventing absorption, but it is added to several activated charcoal products to prevent constipation. For a single dose of charcoal, constipation is typically not a major issue, but it can be problematic if multiple doses are administered. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Cathartics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The dose can be repeated at 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    every four to six hours (without the cathartic) for ingestions of substances that form concretions, sustained-release preparations, to bind drugs with enterohepatic recirculation, and to increase the charcoal-drug ratio in massive ingestions. With multiple doses, the addition of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    to the first dose may help avoid constipation. If available, superactivated charcoal may be preferable in massive ingestions because it allows smaller but equally effective doses to be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032558\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other forms of GI decontamination, the efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    decreases over time. Pooled data from controlled adult volunteer studies showed that mean bioavailability of the ingested drug was reduced by 52 percent when charcoal was administered up to 30 minutes after dosing and by 38 percent at 60 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    is more effective in preventing drug absorption than is either syrup of ipecac or orogastric lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Gastric lavage followed by or preceded and followed by activated charcoal may be more effective at preventing drug absorption than is activated charcoal alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proving that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    positively influences patient outcome has been difficult. As an example, one study randomized 451 asymptomatic overdose patients to either 50 grams of activated charcoal or no GI decontamination treatment and found no differences in clinical course or outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/12\">",
"     12",
"    </a>",
"    ]. Further studies to compare activated charcoal alone versus no GI decontamination in symptomatic patients have not been performed. However, two large controlled clinical studies demonstrated similar efficacies of activated charcoal alone and gastric lavage plus activated charcoal for patients who are treated more than one hour from the time of ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Unfortunately, these studies had insufficient numbers of critically-ill patients who may benefit the most from aggressive decontamination techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032565\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    (AC) is often the only GI decontamination measure needed to treat an overdose. The greatest benefit from AC is seen when it is administered within one hour of ingestion, and when used AC should be administered as soon as possible after patient presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4\">",
"     4",
"    </a>",
"    ]. The decision to use AC is not algorithmic and depends upon the toxin, the clinical status of the patient, and the time since ingestion. Specific recommendations for AC administration can be found in the topic reviews for individual poisons.",
"   </p>",
"   <p>",
"    Multiple-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    can be considered in the treatment of children who have ingested life-threatening amounts of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/12/19655?source=see_link\">",
"     quinine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    . When multiple-dose activated charcoal is used, care must be taken to protect the airway, to continually assess for the presence of bowel sounds, and to avoid multiple doses of cathartics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/6,15\">",
"     6,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032572\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    (AC) is absolutely",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with bowel obstruction or perforation and those with an unprotected airway. AC should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with a depressed level of consciousness until the airway is secured by tracheal intubation. However, we do not advocate performing tracheal intubation solely for the purpose of administering AC. In addition, there are several other settings in which AC administration is",
"    <strong>",
"     not recommended",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have ingested nonabsorbable acidic or alkaline corrosives (eg, sodium or potassium hydroxide, or hydrochloric or sulfuric acid) and who require endoscopy because charcoal will obstruct the view of the endoscopist.",
"     </li>",
"     <li>",
"      In patients who have ingested low-viscosity hydrocarbons (eg, gasoline, kerosene, liquid furniture polish) and who are at high risk for aspiration, unless a lethal adsorbable agent has been coingested [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the agent ingested is not bound by",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef77553 \" href=\"mobipreview.htm?4/37/4700\">",
"       table 3",
"      </a>",
"      ), has already been completely absorbed (ie, delayed presentation), or the risk of complications from AC administration outweighs any perceived clinical benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4,16\">",
"       4,16",
"      </a>",
"      ]. As an example, the benefit of AC may be outweighed by the risk of precipitating GI hemorrhage or perforation in patients with gastric pathology or recent surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10032637\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious adverse effects from single-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    are rare. The most severe adverse effect is pulmonary aspiration of charcoal and gastric contents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/14\">",
"     14",
"    </a>",
"    ]. Deaths caused by improper nasogastric tube placement with instillation of the charcoal into the tracheobronchial tree have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common, less severe, side effects include nausea, vomiting, abdominal cramps, diarrhea (particularly when the drug is used with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/19\">",
"     19",
"    </a>",
"    ]), and bronchiolitis obliterans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/20\">",
"     20",
"    </a>",
"    ]. In one prospective review of 275 consecutive children who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , vomiting occurred in 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/21\">",
"     21",
"    </a>",
"    ]. In multivariable analysis, the risk of vomiting was significantly increased among children who had prior episodes of vomiting (RR 3.4, 95% CI 1.5-7.8) and nasogastric administration (RR 2.4, 95% CI 1.1-5.1). Risk of vomiting was also increased (but not significantly) among children with nausea and those who were &gt;12 years of age. Sorbitol content, charcoal volume, and rate of administration did not affect the risk of emesis.",
"   </p>",
"   <p>",
"    Repeated doses of cathartics in the charcoal slurry may result in electrolyte imbalances (particularly hypernatremia) and hypovolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, constipation and mechanical bowel obstruction can occur in patients receiving repeated doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Syrup of ipecac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syrup of ipecac, which contains the alkaloids cephaline and emetine, induces vomiting through direct and indirect stimulation of the vomiting center in the brain. Vomiting usually begins within 20 minutes after administration and lasts one to two hours. Ninety percent of children will vomit after a single 15 mL dose; 99 percent will vomit after two doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ipecac in the treatment of oral ingestions has decreased dramatically since 1985 (15 versus 0.05 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) no longer recommends the routine home use of ipecac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose &ndash; The recommended doses of ipecac for children older than six months are listed below:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      6 to 12 months &ndash; 5 to 10 mL (1 to 2 tsp) by mouth with 120 to 240 mL (4 to 8 oz) of water",
"     </li>",
"     <li>",
"      1 to 12 years &ndash; 15 mL (3 tsp) by mouth with 120 to 240 mL (4 to 8 oz) of water",
"     </li>",
"     <li>",
"      Older than 12 years &ndash; 15 to 30 mL (3 to 6 tsp) by mouth with 240 mL (8 oz) of water",
"      <br/>",
"      <br/>",
"      The dose can be repeated if vomiting does not occur after 20 to 30 minutes. The use of ipecac beyond the expiration date is",
"      <strong>",
"       not",
"      </strong>",
"      contraindicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy &ndash; Experimental studies in animals and human volunteers show that recovery of ingested material is highly variable and rapidly diminishes with time. In controlled human volunteer studies, ipecac decreased poison absorption by a mean of 25 percent when administered 30 minutes after ingestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/26-30\">",
"       26-30",
"      </a>",
"      ], and 23 percent when given at 60 minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10,26,27,29-33\">",
"       10,26,27,29-33",
"      </a>",
"      ]. Ipecac is less effective than activated charcoal and approximately equivalent to gastric lavage in reducing poison absorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10,28,32,33\">",
"       10,28,32,33",
"      </a>",
"      ]. As an example, one study of 10 volunteers using an ampicillin overdose model found that absorption was reduced by 32 percent by gastric lavage, 38 percent by ipecac-induced emesis, and 57 percent with activated charcoal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The utility of ipecac in conjunction with other decontamination modalities is not well supported by experimental data. Four clinical studies have shown no improvement in patient outcomes from the administration of ipecac before activated charcoal versus activated charcoal alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/12-14,34\">",
"       12-14,34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The use of ipecac alone has demonstrated some clinical benefit when used in the home. In one study of acetaminophen ingestions in children, those receiving ipecac within one hour of ingestion had significantly lower serum concentrations compared with those who were not decontaminated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indications &ndash; Syrup of ipecac should",
"      <strong>",
"       not",
"      </strong>",
"      be administered routinely in the hospital setting since activated charcoal has shown greater efficacy, and there is no evidence that syrup of ipecac alone improves outcomes in that setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/25\">",
"       25",
"      </a>",
"      ]. Ipecac is an acceptable treatment",
"      <strong>",
"       only",
"      </strong>",
"      in an alert, conscious patient who has ingested a substantial amount of a toxic substance within the previous 60 minutes ingestion and after consultation with a health care provider or poison control center (1-800-222-1222) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/25\">",
"       25",
"      </a>",
"      ]. Thus, its primary utility is in the prehospital setting immediately following a witnessed ingestion. This role may be usurped in the near future by the administration of activated charcoal.",
"      <br/>",
"      <br/>",
"      Controversy exists as to whether ipecac has any place in the management of poisoned children:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The American Academy of Clinical Toxicology and the European Association of Poisons Centres and Clinical Toxicologists position statement on ipecac syrup states that ipecac should not be used routinely in the management of poisoned patients because no evidence exists from clinical studies that it improves their outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/25\">",
"       25",
"      </a>",
"      ]. The AAP no longer recommends the routine home use of ipecac and recommends that parents be advised to safely dispose of any ipecac currently in the home [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/24\">",
"       24",
"      </a>",
"      ]. The AAP recommends caregivers of children who have ingested a toxic substance consult with the local poison control center (1-800-222-1222) for management advice.",
"     </li>",
"     <li>",
"      The American Medical Association and the Canadian Task Force on Preventive Health Care recommend that parents of young children keep a bottle of ipecac in the home [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. In addition, they recommend that parents know the phone number of a poison control center (1-800-222-1222) and receive counseling on poison prevention.",
"     </li>",
"     <li>",
"      The American College of Emergency Physicians makes no definitive recommendation regarding the use of syrup of ipecac [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contraindications &ndash; In addition to its limited indications, ipecac is contraindicated in the following situations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/3,25\">",
"       3,25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The child is younger than six months",
"     </li>",
"     <li>",
"      A nontoxic substance has been ingested",
"     </li>",
"     <li>",
"      Depressed mental status is present (eg, coma, seizure)",
"     </li>",
"     <li>",
"      Depressed gag reflex is present or anticipated (eg, rapidly acting central nervous system depressants)",
"     </li>",
"     <li>",
"      A corrosive agent has been ingested (eg, alkali or strong acid)",
"     </li>",
"     <li>",
"      Low viscosity hydrocarbons have been ingested, yielding a high risk of aspiration if vomiting occurs",
"     </li>",
"     <li>",
"      Repeated vomiting poses a health danger (eg, recent GI surgery, third trimester of pregnancy, severe hypertension)",
"     </li>",
"     <li>",
"      The child has coagulopathy or bleeding diathesis",
"     </li>",
"     <li>",
"      Cardiotoxic drugs that can worsen bradycardia have been ingested (eg, calcium-channel blockers, beta blockers),",
"      <strong>",
"       unless",
"      </strong>",
"      it is very early in the ingestion and a sustained release preparation has been ingested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse effects &ndash; Adverse effects from the therapeutic use of ipecac for poisoning emergencies are extremely uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most common adverse effects are protracted vomiting, sedation, and diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Forceful and protracted vomiting can cause Mallory-Weiss tears, pneumomediastinum, gastric rupture, traumatic diaphragmatic hernia, intracerebral hemorrhage, and bradycardia from vagal stimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/39,42\">",
"       39,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sedation or seizures can lead to aspiration of gastric contents.",
"     </li>",
"     <li>",
"      The chronic use or abuse of ipecac can result in cardiomyopathy, myopathy, metabolic disturbances, shock, and death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/39,43\">",
"       39,43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, the administration of ipecac can delay or complicate emergency department management [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/25,38\">",
"       25,38",
"      </a>",
"      ]. In one prospective, randomized trial, seventy children who presented to the emergency department with a toxic ingestion were randomized to receive both syrup of ipecac and activated charcoal or activated charcoal alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/44\">",
"       44",
"      </a>",
"      ]. Administration of syrup of ipecac delayed the administration of activated charcoal (2.6 versus 0.9 hours), increased the amount of time spent in the emergency department (4.1 versus 3.4 hours), and increased the likelihood of vomiting the activated charcoal (18 of 32 versus 6 of 38).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastric lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric lavage, another method used to remove the stomach contents after a toxic ingestion, was performed in less than 1 percent of all toxic ingestions in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical benefit of gastric lavage has not been confirmed in controlled studies, and its routine use in the management of poisoned patients is",
"    <strong>",
"     no longer recommended",
"    </strong>",
"    by the American Academy of Clinical Toxicology or the European Association of Poisons Centres and Clinical Toxicologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6605178\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orogastric lavage should be performed by a physician who is familiar with the technique. The presence of the child's gag reflex should be confirmed, and the child should be properly restrained in the left lateral decubitus position with the head 15 to 20 degrees lower than the feet (Trendelenburg position) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/45\">",
"     45",
"    </a>",
"    ]. The largest possible tube (up to 24 French in infants) with side holes should be carefully inserted through the mouth and its proper position verified by air insufflation into the stomach or retrieval of gastric contents. The stomach contents should be emptied, and then lavage should be performed with 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    (up to 200 to 300 mL) aliquots until the effluent is clear. The lavage solution should be warm normal saline or tap water to prevent hypothermia. Hemodilution has not been reported unless excessive quantities of tap water are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies support the use of charcoal before lavage, which will absorb the toxin, serve as a guide for completion of lavage, and also adsorb any toxic substance that may be pushed beyond the pylorus during lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/11,47\">",
"     11,47",
"    </a>",
"    ]. After lavage, a dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    can be administered before removal of the tube. This method is time-consuming, but should be considered for all life-threatening overdoses that present near the time of ingestion, especially in with poisons in which a relatively small amount of absorption can be lethal (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    , methyl salicylate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10032536\">",
"     'Dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical data on the efficacy of orogastric lavage in pediatric patients exist. Experimental studies in animals and human volunteers show that recovery of ingested material with the use of gastric lavage is highly variable and diminishes with time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/26,45\">",
"     26,45",
"    </a>",
"    ]. Gastric lavage decreases the absorption of ingested poison by an average of 26 percent when performed 30 minutes after ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] and 12 percent when performed at 60 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10,26,32\">",
"     10,26,32",
"    </a>",
"    ]. A study in which poisoned patients underwent endoscopy after gastric lavage found that 88 percent of patients had residual solid material in the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric lavage is less effective than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    in reducing the absorption of simulated toxins, but is roughly equivalent in efficacy to ipecac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10\">",
"     10",
"    </a>",
"    ]. Gastric lavage in combination with activated charcoal (administered either before lavage or both before and after lavage) is more effective in reducing drug absorption than is activated charcoal given alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/11\">",
"     11",
"    </a>",
"    ], but studies have not confirmed a clinical benefit of gastric lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric lavage may be of benefit if a child has ingested a potentially toxic amount of a substance and the procedure can be performed within one hour of ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/13,45\">",
"     13,45",
"    </a>",
"    ]. It may also be used in children who present more than one hour after ingestion and who have ingested highly toxic substances, substances that are not well bound to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/38\">",
"     38",
"    </a>",
"    ], or substances with anticholinergic properties that delay gastric emptying. However, its clinical benefit in these situations has not been confirmed in controlled studies. For the vast majority of patients, particularly those that present late or are asymptomatic on presentation, gastric lavage is",
"    <strong>",
"     not",
"    </strong>",
"    likely to add benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its limited indications, gastric lavage is contraindicated in children who have ingested corrosive materials, are uncooperative with the procedure, or are at risk for hemorrhage or perforation because of esophageal or gastric pathology or recent surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/45\">",
"     45",
"    </a>",
"    ]. In children who are at risk for aspiration (eg, ingestion of central nervous system depressants, low-viscosity hydrocarbons, or substances that lower the seizure threshold), the airway should be protected by endotracheal intubation before orogastric lavage; however, endotracheal intubation does not completely eliminate the risk of pulmonary aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 percent of patients will have a complication related to gastric lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10\">",
"     10",
"    </a>",
"    ]. Potential complications include pharyngeal, esophageal or gastric injury, inadvertent administration of lavage fluid into the tracheobronchial tree, hypoxemia and hypercapnia, laryngospasm, cardiac ischemia or arrhythmia, pneumothorax, electrolyte disturbances, hypothermia, and propulsion of stomach contents beyond the pylorus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/45,47,50\">",
"     45,47,50",
"    </a>",
"    ]. Gastric lavage is associated with an increased risk of aspiration and intensive care unit admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Whole bowel irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole bowel irrigation (WBI) refers to the administration of large volumes of a balanced electrolyte irrigating solution with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    , usually via a nasogastric tube, to decontaminate the GI tract without causing fluid or electrolyte shifts. One pediatric case report described the administration of 44 liters of WBI solution to a 33-month-old child without ill effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/51\">",
"     51",
"    </a>",
"    ]. WBI was used in fewer than 1 percent of ingestions in 2002, and its role in the treatment of childhood poisoning has not been well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the usual dose is 20 to 40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour until the rectal effluent is clear, which typically takes four to six hours. The",
"    <strong>",
"     maximum",
"    </strong>",
"    recommended doses for children older than nine months are listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      9 months to 6 years &ndash; 500",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"     </li>",
"     <li>",
"      6 to 12 years &ndash; 1000",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"     </li>",
"     <li>",
"      Older than 12 years &ndash; 1500 to 2000",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If vomiting occurs, the infusion rate can be decreased or an intravenous antiemetic drug, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , can be administered. The solution can be given orally or via a nasogastric tube once proper tube position has been confirmed. Warming of the solution should be considered to prevent hypothermia, but it has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three controlled human studies in which overdoses were simulated have shown that WBI significantly decreased absorption of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    (by 67 percent), enteric-coated",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    (by 73 percent), and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    (by 67 percent) when treatment was initiated between one and four hours after ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. No controlled clinical trials have been performed to test the efficacy of WBI in actual toxic ingestions. Case reports suggest that WBI is effective following the ingestion of iron, sustained-release",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    , latex packets of cocaine, lead, arsenic, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/39/29301?source=see_link\">",
"     zinc sulfate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/52,56-62\">",
"     52,56-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for whole bowel irrigation in children are the ingestion of enteric-coated pills, sustained-release preparations, illicit drug packets, and large ingestions of substances poorly bound by charcoal, such as iron,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    and lead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/38,52,63\">",
"     38,52,63",
"    </a>",
"    ]. &nbsp;WBI also may be of benefit in children with suspected drug concretions (pharmacobezoars) in the GI tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to WBI include intestinal obstruction, perforation, ileus, or significant gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/52\">",
"     52",
"    </a>",
"    ]. Endotracheal intubation should precede WBI in children who require airway management or have depressed mental status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of WBI are nausea, vomiting, abdominal cramps, bloating, and aspiration pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/3,54\">",
"     3,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cathartics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cathartics accelerate the evacuation of the gastrointestinal contents, including toxin or toxin-adsorbent complex, by increasing the fluid load in the intestine and stimulating bowel motility. They should",
"    <strong>",
"     never",
"    </strong>",
"    be used as the sole method of GI decontamination.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     Sorbitol",
"    </a>",
"    is the preferred agent in children because of its greater efficacy and palatability compared with saline cathartics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose &ndash; Use of cathartics should be limited to a single dose because repetitive dosing can cause adverse effects. This limitation is of particular importance for small children, who can become hypovolemic if more than one dose is administered. Recommended pediatric doses of commonly used agents are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      0.5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      of 70 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      (0.9",
"      <span class=\"nowrap\">",
"       g/mL)",
"      </span>",
"     </li>",
"     <li>",
"      4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      or 250 mL of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34403?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      in a 6 percent suspension",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"       Sorbitol",
"      </a>",
"      is not recommended for use in children younger than one year of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy &ndash; One human volunteer study found that a mixture of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      resulted in significantly shorter GI transit times than when charcoal was mixed with water (0.9 versus 23.5 hours) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/65\">",
"       65",
"      </a>",
"      ]. However, cathartics have not been conclusively shown to reduce drug absorption, morbidity, mortality, or duration of hospitalization when used alone or in combination with activated charcoal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indications &ndash; Cathartics are suggested in patients who will receive more than one dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      . In these patients, cathartics (typically",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      ) can be given with the first dose of activated charcoal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Contraindications &ndash; Cathartics are contraindicated in children with intestinal obstruction, perforation, ileus, electrolyte imbalances, hypotension, or hypovolemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/64\">",
"       64",
"      </a>",
"      ]. Magnesium cathartics should not be administered to children with renal failure because some of the magnesium is absorbed, possibly leading to hypermagnesemia.",
"     </li>",
"     <li>",
"      Adverse effects &ndash; The use of multiple doses of cathartics has been associated with electrolyte disturbances, hypovolemia, excessive diarrhea, nausea, and vomiting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/22,64\">",
"       22,64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Endoscopy and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic removal should be considered for children who have a life-threatening amount of a substance in the stomach (eg, bezoars, concretions) that cannot be safely removed by other means [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/66\">",
"     66",
"    </a>",
"    ]. Endoscopy also can be used to remove foreign bodies such as large coins or batteries; however, some of these materials are difficult to grasp with the endoscope and may require surgical removal. Surgical removal also is indicated for cocaine packets because the packets may rupture if endoscopic removal is attempted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/67\">",
"     67",
"    </a>",
"    ], and for life-threatening gastric iron bezoars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Dilution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilution is utilized only for ingestions of corrosive substances such as acids or alkali. The recommended pediatric doses are 120 to 180 mL (4 to 6 oz) of water. Larger doses may induce vomiting. Studies using a canine model have shown that dilution does not increase the temperature or intraluminal pressure in the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Airway patency must always be assessed before giving fluids by mouth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     DERMAL EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermal exposures accounted for 7.8 percent of reported toxic exposures and 1.7 percent of fatal toxic exposures in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ]. Toxins associated with systemic toxicity after dermal absorption are listed in table 4 (",
"    <a class=\"graphic graphic_table graphicRef79115 \" href=\"mobipreview.htm?5/45/5853\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial treatment for any dermal exposure is immediate decontamination, beginning with manual removal of contaminated clothing and particulate matter. Prehospital and hospital personnel caring for children with dermal exposures should wear protective gear to protect themselves from dermal, inhalation, and ocular exposure during the decontamination process. The clinical effects of chemical burns often are delayed in onset; observation and reassessment are necessary to prevent undertreatment.",
"   </p>",
"   <p>",
"    The method of decontamination and the irrigation solution depend upon the agent of exposure. Decontamination procedures for solids and liquids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H2#H2\">",
"     \"Topical chemical burns\", section on 'Principles of management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H16#H16\">",
"     \"Topical chemical burns\", section on 'Specific agents and treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     OCULAR EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular exposure occurred in 5.2 percent of reported toxic exposures and 2 percent of fatal exposures in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ]. Chemical ocular exposure is an ophthalmologic emergency and should be managed in conjunction with an ophthalmologist. Irrigation should begin immediately at the exposure site (eg, home, school) and continue in the emergency department. Visual acuity testing should be deferred until after irrigation is complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Liquids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decontamination of ocular exposures begins with removal of contact lenses and application of topical anesthesia (if available), followed by irrigation with at least one liter of normal saline (or the most rapidly available solution) per eye. For alkali or severe acid burns, irrigation is continued until the conjunctival pH is 6.5 to 8.0; prolonged irrigation may be required to achieve a neutral pH. If tolerated, the use of a Morgan lens is helpful when performing prolonged eye irrigation (",
"    <a class=\"graphic graphic_figure graphicRef51399 \" href=\"mobipreview.htm?28/19/28989\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63134 \" href=\"mobipreview.htm?39/43/40638\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74905 \" href=\"mobipreview.htm?25/57/26513\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53892 \" href=\"mobipreview.htm?20/54/21346\">",
"     picture 3",
"    </a>",
"    ). The procedure for eye irrigation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H9#H9\">",
"     \"Topical chemical burns\", section on 'Eye exposure'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Solids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid or particulate matter that can cause persistent injury and corneal abrasion can be detected by eversion of the eyelids and gently removed with a cotton-tipped swab. Irrigation and pH measurements then are performed as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     INHALATION EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalation exposures accounted for 6.2 percent of reported poisonings and 7.8 percent of poisoning deaths in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"     2",
"    </a>",
"    ]. Most pediatric inhalational exposures are unintentional. In cases of accidental exposures, the children should be removed as soon as possible from the source and offered fresh air. More serious exposures may require rescue from the contaminated environment by emergency personnel who are equipped with respiratory protection. The children should be treated with supplemental oxygen; early endotracheal intubation is recommended if signs of progressive airway compromise are present. Beta-adrenergic agents and corticosteroids can be helpful in treating associated bronchospasm and airway inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Carbon monoxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide, one of the principal causes of poisoning morbidity and mortality, is a colorless, odorless gas that is produced by the incomplete combustion of many carbon-containing products (eg, butane, propane, natural gas, gasoline, etc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37913/abstract/72\">",
"     72",
"    </a>",
"    ]. Carbon monoxide binds to hemoglobin with greater affinity than does oxygen and impairs oxygen delivery to the tissues.",
"   </p>",
"   <p>",
"    Treatment of carbon monoxide poisoning begins with removal of the child from the source and administration of 100 percent oxygen. The administration of 100 percent oxygen reduces the half-life of carboxyhemoglobin from 4.5 to 1.5 hours; the half-life of carboxyhemoglobin can be further reduced (to 0.5 hours) by treatment with hyperbaric oxygen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10345?source=see_link&amp;anchor=H11#H11\">",
"     \"Carbon monoxide poisoning\", section on 'Initial treament and disposition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10345?source=see_link&amp;anchor=H12#H12\">",
"     \"Carbon monoxide poisoning\", section on 'Hyperbaric oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16099805\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decontamination refers to the techniques used to prevent the absorption of the toxic substance by the body. Assessment and management of airway, breathing, and circulation takes priority over decontamination techniques in the critically-ill child with a toxic exposure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decontamination methods vary according to the route of exposure (oral, dermal, ocular, inhalation), the time elapsed since the exposure, and the expected toxicity of the exposure. Regardless of the method employed, efficacy decreases with increased time between exposure and treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      is the primary means of gastrointestinal (GI) decontamination after ingestion of a toxic substance. Important contraindications include a compromised and unprotected airway, ingestion of a caustic substance, and hydrocarbon ingestion. Some toxic agents do not bind well to activated charcoal (",
"      <a class=\"graphic graphic_table graphicRef77553 \" href=\"mobipreview.htm?4/37/4700\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oral exposures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10032467\">",
"       'Activated charcoal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10032572\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other modalities (eg, syrup of ipecac, gastric lavage, whole bowel irrigation, and endoscopic or surgical removal of the ingested poison) are less effective for removing ingested toxins and are infrequently employed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Syrup of ipecac'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Gastric lavage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Whole bowel irrigation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Endoscopy and surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For dermal exposures, use personal protective equipment appropriate to the contaminant, remove clothing, brush away any solids, and irrigate copiously. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Dermal exposures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H2#H2\">",
"       \"Topical chemical burns\", section on 'Principles of management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For ocular exposures, irrigate copiously the eyes with the goal of returning the tears to a neutral pH. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Ocular exposures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H9#H9\">",
"       \"Topical chemical burns\", section on 'Eye exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with inhalational poisoning should be removed from the source of the exposure and offered fresh air. Supplemental oxygen, advanced airway maneuvers, and treatment for bronchospasm may also be necessary. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Inhalation exposures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with a regional poison control center or medical toxicologist is available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that make management decisions unclear. (See",
"      <a class=\"local\" href=\"#H16099805\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/1\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/2\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/3\">",
"      Shannon M. Ingestion of toxic substances by children. N Engl J Med 2000; 342:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/4\">",
"      Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol 2005; 43:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/5\">",
"      Roberts JR, Gracely EJ, Schoffstall JM. Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model. Acad Emerg Med 1997; 4:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/6\">",
"      Burns MM. Activated charcoal as the sole intervention for treatment after childhood poisoning. Curr Opin Pediatr 2000; 12:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/7\">",
"      Eisen TF, Grbcich PA, Lacouture PG, et al. The adsorption of salicylates by a milk chocolate-charcoal mixture. Ann Emerg Med 1991; 20:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/8\">",
"      Guenther Skokan E, Junkins EP Jr, Corneli HM, Schunk JE. Taste test: children rate flavoring agents used with activated charcoal. Arch Pediatr Adolesc Med 2001; 155:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/9\">",
"      Dagnone D, Matsui D, Rieder MJ. Assessment of the palatability of vehicles for activated charcoal in pediatric volunteers. Pediatr Emerg Care 2002; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/10\">",
"      Tenenbein M, Cohen S, Sitar DS. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med 1987; 16:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/11\">",
"      Burton BT, Bayer MJ, Barron L, Aitchison JP. Comparison of activated charcoal and gastric lavage in the prevention of aspirin absorption. J Emerg Med 1984; 1:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/12\">",
"      Merigian KS, Woodard M, Hedges JR, et al. Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med 1990; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/13\">",
"      Kulig K, Bar-Or D, Cantrill SV, et al. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med 1985; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/14\">",
"      Pond SM, Lewis-Driver DJ, Williams GM, et al. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust 1995; 163:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/15\">",
"      Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999; 37:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/16\">",
"      Bond GR. The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med 2002; 39:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/17\">",
"      Litovitz TL, Klein-Schwartz W, Dyer KS, et al. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1998; 16:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/18\">",
"      Harris CR, Filandrinos D. Accidental administration of activated charcoal into the lung: aspiration by proxy. Ann Emerg Med 1993; 22:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/19\">",
"      Harchelroad F, Cottington E, Krenzelok EP. Gastrointestinal transit times of a charcoal/sorbitol slurry in overdose patients. J Toxicol Clin Toxicol 1989; 27:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/20\">",
"      Elliott CG, Colby TV, Kelly TM, Hicks HG. Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest 1989; 96:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/21\">",
"      Osterhoudt KC, Durbin D, Alpern ER, Henretig FM. Risk factors for emesis after therapeutic use of activated charcoal in acutely poisoned children. Pediatrics 2004; 113:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/22\">",
"      Farley TA. Severe hypernatremic dehydration after use of an activated charcoal-sorbitol suspension. J Pediatr 1986; 109:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/23\">",
"      Krenzelok EP, Dean BS. Effectiveness of 15-mL versus 30-mL doses of syrup of ipecac in children. Clin Pharm 1987; 6:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/24\">",
"      American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Pediatrics 2003; 112:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/25\">",
"      Position paper: Ipecac syrup. J Toxicol Clin Toxicol 2004; 42:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/26\">",
"      Abdallah AH, Tye A. A comparison of the efficacy of emetic drugs and stomach lavage. Am J Dis Child 1967; 113:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/27\">",
"      ARNOLD FJ Jr, HODGES JB Jr, BARTA RA Jr. Evaluation of the efficacy of lavage and induced emesis in treatment of salicylate poisoning. Pediatrics 1959; 23:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/28\">",
"      Neuvonen PJ, Vartiainen M, Tokola O. Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol 1983; 24:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/29\">",
"      Saincher A, Sitar DS, Tenenbein M. Efficacy of ipecac during the first hour after drug ingestion in human volunteers. J Toxicol Clin Toxicol 1997; 35:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/30\">",
"      Vasquez TE, Evans DG, Ashburn WL. Efficacy of syrup of ipecac-induced emesis for emptying gastric contents. Clin Nucl Med 1988; 13:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/31\">",
"      Minton NA, Glucksman E, Henry JA. Prevention of drug absorption in simulated theophylline overdose. Hum Exp Toxicol 1995; 14:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/32\">",
"      Danel V, Henry JA, Glucksman E. Activated charcoal, emesis, and gastric lavage in aspirin overdose. Br Med J (Clin Res Ed) 1988; 296:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/33\">",
"      McNamara RM, Aaron CK, Gemborys M, Davidheiser S. Efficacy of charcoal cathartic versus ipecac in reducing serum acetaminophen in a simulated overdose. Ann Emerg Med 1989; 18:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/34\">",
"      Albertson TE, Derlet RW, Foulke GE, et al. Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions. Ann Emerg Med 1989; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/35\">",
"      Kirk, MA, Peterson, J, Kulig, K, et al. Acetaminophen overdose in children: a comparison of ipecac versus activated charcoal versus no gastrointestinal decontamination [abstract]. Ann Emerg Med 1991; 20:472.",
"     </a>",
"    </li>",
"    <li>",
"     Elford, RW. Prevention of household and recreational injuries in children (&lt;15 years of age). In: Canadian Task Force on the Periodic Health Examination: Canadian Guide to Clinical Preventive Health Care, Health Canada, Ottawa 1994. p.306.",
"    </li>",
"    <li>",
"     www.ama-assn.org/apps/pf_new/pf_online?f_n=browse&amp;doc=policyfiles/HnE/H-60.998.HTM AMA Policy H-60.998. Ipecac as household poison emetic (Accessed on March 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/38\">",
"      Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/39\">",
"      Quang LS, Woolf AD. Past, present, and future role of ipecac syrup. Curr Opin Pediatr 2000; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/40\">",
"      Chafee-Bahamon C, Lacouture PG, Lovejoy FH Jr. Risk assessment of ipecac in the home. Pediatrics 1985; 75:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/41\">",
"      Czajka PA, Russell SL. Nonemetic effects of ipecac syrup. Pediatrics 1985; 75:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/42\">",
"      Hantsch CE, Seger DL, Meredith T. New thinking on gastrointestinal decontamination. Ped Emerg Med Reports 1998; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/43\">",
"      Palmer EP, Guay AT. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. N Engl J Med 1985; 313:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/44\">",
"      Kornberg AE, Dolgin J. Pediatric ingestions: charcoal alone versus ipecac and charcoal. Ann Emerg Med 1991; 20:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/45\">",
"      Vale JA. Position statement: gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/46\">",
"      Chen X, Huang G. Autopsy case report of a rare acute iatrogenic water intoxication with a review of the literature. Forensic Sci Int 1995; 76:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/47\">",
"      Saetta JP, March S, Gaunt ME, Quinton DN. Gastric emptying procedures in the self-poisoned patient: are we forcing gastric content beyond the pylorus? J R Soc Med 1991; 84:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/48\">",
"      Saetta JP, Quinton DN. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study. J R Soc Med 1991; 84:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/49\">",
"      Moll J, Kerns W 2nd, Tomaszewski C, Rose R. Incidence of aspiration pneumonia in intubated patients receiving activated charcoal. J Emerg Med 1999; 17:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/50\">",
"      Thompson AM, Robins JB, Prescott LF. Changes in cardiorespiratory function during gastric lavage for drug overdose. Hum Toxicol 1987; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/51\">",
"      Kaczorowski JM, Wax PM. Five days of whole-bowel irrigation in a case of pediatric iron ingestion. Ann Emerg Med 1996; 27:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/52\">",
"      Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/53\">",
"      Tenenbein M, Cohen S, Sitar DS. Whole bowel irrigation as a decontamination procedure after acute drug overdose. Arch Intern Med 1987; 147:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/54\">",
"      Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989; 46:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/55\">",
"      Smith SW, Ling LJ, Halstenson CE. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med 1991; 20:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/56\">",
"      Burkhart KK, Wuerz RC, Donovan JW. Whole-bowel irrigation as adjunctive treatment for sustained-release theophylline overdose. Ann Emerg Med 1992; 21:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/57\">",
"      Smith SW, Ling LJ, Halstenson CE. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med 1991; 20:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/58\">",
"      Tenenbein M. Whole bowel irrigation in iron poisoning. J Pediatr 1987; 111:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/59\">",
"      Hoffman RS, Smilkstein MJ, Goldfrank LR. Whole bowel irrigation and the cocaine body-packer: a new approach to a common problem. Am J Emerg Med 1990; 8:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/60\">",
"      Burkhart KK, Kulig KW, Rumack B. Whole-bowel irrigation as treatment for zinc sulfate overdose. Ann Emerg Med 1990; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/61\">",
"      Roberge RJ, Martin TG. Whole bowel irrigation in an acute oral lead intoxication. Am J Emerg Med 1992; 10:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/62\">",
"      Lee DC, Roberts JR, Kelly JJ, Fishman SM. Whole-bowel irrigation as an adjunct in the treatment of radiopaque arsenic. Am J Emerg Med 1995; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/63\">",
"      Perrone J, Hoffman RS, Goldfrank LR. Special considerations in gastrointestinal decontamination. Emerg Med Clin North Am 1994; 12:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/64\">",
"      Position paper: cathartics. J Toxicol Clin Toxicol 2004; 42:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/65\">",
"      Krenzelok EP, Keller R, Stewart RD. Gastrointestinal transit times of cathartics combined with charcoal. Ann Emerg Med 1985; 14:1152.",
"     </a>",
"    </li>",
"    <li>",
"     Smilkstein, MJ. Techniques used to prevent gastrointestinal absorption of toxic compounds. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank, LE, et al (Eds), Appleton &amp; Lange, Stamford 1998. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/67\">",
"      Trent MS, Kim U. Cocaine packet ingestion. Surgical or medical management? Arch Surg 1987; 122:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/68\">",
"      Peterson CD, Fifield GC. Emergency gastrotomy for acute iron poisoning. Ann Emerg Med 1980; 9:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/69\">",
"      Landsman I, Bricker JT, Reid BS, Bloss RS. Emergency gastrotomy: treatment of choice for iron bezoar. J Pediatr Surg 1987; 22:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/70\">",
"      Homan CS, Maitra SR, Lane BP, et al. Effective treatment for acute alkali injury to the esophagus using weak-acid neutralization therapy: an ex-vivo study. Acad Emerg Med 1995; 2:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/71\">",
"      Homan CS, Maitra SR, Lane BP, et al. Histopathologic evaluation of the therapeutic efficacy of water and milk dilution for esophageal acid injury. Acad Emerg Med 1995; 2:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37913/abstract/72\">",
"      Cobb N, Etzel RA. Unintentional carbon monoxide-related deaths in the United States, 1979 through 1988. JAMA 1991; 266:659.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6499 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-210.101.131.232-F6895ED81D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37913=[""].join("\n");
var outline_f37_1_37913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ORAL EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10032467\">",
"      Activated charcoal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10032536\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10032558\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10032565\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10032572\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10032637\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Syrup of ipecac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastric lavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6605178\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Whole bowel irrigation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cathartics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Endoscopy and surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Dilution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      DERMAL EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      OCULAR EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Liquids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Solids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      INHALATION EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16099805\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6499|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/19/28989\" title=\"figure 1\">",
"      Morgan lens close up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6499|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/43/40638\" title=\"picture 1\">",
"      Morgan lens flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/57/26513\" title=\"picture 2\">",
"      Morgan lens insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/54/21346\" title=\"picture 3\">",
"      Morgan lens removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/62/18411\" title=\"table 1\">",
"      Agents most commonly ingested by children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/18/4395\" title=\"table 2\">",
"      Agents causing fatal poisoning in young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/37/4700\" title=\"table 3\">",
"      Agents for which activated charcoal is not recommended",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/45/5853\" title=\"table 4\">",
"      Agents with systemic toxicity after skin exposure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=related_link\">",
"      Topical chemical burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37914="Treatment and prognosis of primary central nervous system lymphoma";
var content_f37_1_37914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of primary central nervous system lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     Fred H Hochberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/1/37914/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/1/37914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary central nervous system lymphoma (PCL) is an uncommon variant of extranodal non-Hodgkin lymphoma (NHL) that involves the brain, leptomeninges, eyes, or spinal cord without evidence of systemic disease.",
"   </p>",
"   <p>",
"    The treatment, complications, and prognosis of PCL will be reviewed here. The clinical and pathologic features of this disorder, as well as the treatment of secondary involvement of the CNS by lymphoma originating outside the CNS, are discussed separately. In addition, a discussion of PCL in HIV positive patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation of patients with PCL both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with PCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies including a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), and serologic testing for HIV.",
"     </li>",
"     <li>",
"      Full ophthalmological evaluation including slit lamp examination of both eyes is strongly recommended, even in the absence of visual symptoms, since ocular lymphoma occurs in up to 20 percent of patients, and may be followed by reseeding of brain sites. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Slit lamp examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lumbar puncture is recommended for all patients, unless contraindicated, as cerebrospinal fluid dissemination is detected in 15 to 40 percent of PCL patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Cerebrospinal fluid analysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A gadolinium-enhanced magnetic resonance imaging (MRI) of the brain is recommended for all patients. MRI of the spine is directed based upon symptoms (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60130 \" href=\"mobipreview.htm?1/1/1043\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Radiographic features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis should be performed to confirm the absence of systemic disease; occult systemic disease may be found in up to 8 percent of patients initially suspected of having PCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/1\">",
"       1",
"      </a>",
"      ]. Some centers may consider a combined",
"      <span class=\"nowrap\">",
"       CT/PET",
"      </span>",
"      (positron emission tomography) scan, if available.",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is suggested for all patients.",
"     </li>",
"     <li>",
"      Testicular ultrasound should be performed in the evaluation of all elderly men with PCL or of younger men who have testicular abnormalities on clinical examination.",
"     </li>",
"     <li>",
"      Performance status should be evaluated and recorded with either the Eastern Cooperative Oncology Group (ECOG) performance scale (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      ) or the Karnofsky performance scale (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Evaluation of cognitive function at baseline should be performed. The ideal measure of cognitive function has yet to be determined but would evaluate attention, executive functions, verbal memory, and motor speed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/2\">",
"       2",
"      </a>",
"      ]. At a minimum, a mini-mental state examination should be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Given the urgent need for treatment, options for women are limited, but men can often participate in sperm banking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated PCL has a rapidly fatal course, with survival of approximately 1.5 months from the time of diagnosis. Survival after whole brain radiation therapy ranges from 10 to 18 months, but increases to an average of 44 months following chemotherapy plus radiation, or chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. Although currently available therapeutic regimes prolong survival, they are not curative in most patients. The disease therefore tends to recur and is eventually fatal.",
"   </p>",
"   <p>",
"    Standard combination chemotherapy regimens, which are useful in the treatment of systemic lymphoma (eg, CHOP), are either ineffective or toxic in the treatment of PCL and should not be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Instead, the main treatment modalities with activity in PCL are alternative types of systemic chemotherapy, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and whole brain radiation therapy. Surgery has a limited, mainly diagnostic, role.",
"   </p>",
"   <p>",
"    The optimal treatment of PCL is unknown and there is variation in clinical practice. The data supporting our treatment approach are described in the following sections. There have been numerous prospective and retrospective case series evaluating different treatment options. Only two randomized trials have been completed. Unfortunately, the results of completed phase II trials are difficult to directly compare due to differences in response definitions and follow-up. Patients should be encouraged to participate in clinical trials, when available. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Methotrexate-based induction chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PCL is primarily treated with a high-dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based regimen with or without whole brain radiation therapy. The role of whole brain radiation therapy in PCL is controversial due to its late complications, especially in older adults. Treatment decisions should take into consideration both response rates and impact on quality of life. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'With chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is incorporated into the standard therapy of most CD20 positive non-Hodgkin lymphomas, including diffuse large B cell lymphoma. While the vast majority of PCL express CD20, the role of rituximab in the treatment of PCL is less clear largely because of the unknown ability of rituximab to cross the blood-brain-barrier. Case reports and single-arm prospective trials have included rituximab into the treatment of newly diagnosed or relapsed PCL, and suggest that it has activity in PCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. If a regimen that incorporates rituximab is used, clinicians must be aware that rituximab therapy imposes a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general treatment principles for PCL apply to most disease presentations and patient populations. However, involvement of the eye or cerebrospinal fluid has unique therapeutic implications. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Special scenarios'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methotrexate-based induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from several retrospective and prospective trials indicate an improvement in survival for patients treated initially with chemotherapy, compared with those treated with radiation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Chemotherapy regimens that employ high dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    appear more effective against PCL than regimens that do not contain methotrexate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with PCL, we recommend the use of high dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (ie, 3.5 to 8",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    either alone or in combination. For patients with a good performance status (ie, ECOG &le;3) who choose not to participate in a clinical trial, we suggest the combination of methotrexate plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or the combination of methotrexate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    , rather than methotrexate alone. Radiation is typically deferred in most patients, except in the subpopulation who have a contraindication to chemotherapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Is there a role for radiation therapy?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For younger patients with a good performance status, the goal of induction therapy is to achieve a complete response with plans to consider high-dose chemotherapy with autologous hematopoietic cell transplantation (rescue), ideally within the context of a clinical trial. (See",
"    <a class=\"local\" href=\"#H9112617\">",
"     'Is there a role for transplant?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23594407\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small prospective trials and retrospective analyses have demonstrated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    's activity as a single agent given systemically, intra-arterially, or in combination with other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/5,20-26\">",
"     5,20-26",
"    </a>",
"    ]. Complete responses are seen in 30 to 60 percent of patients treated with chemotherapy alone. The optimal high dose methotrexate-based regimen for PCL is unknown and there is variation in clinical practice. Patients should be encouraged to participate in clinical trials, when available.",
"   </p>",
"   <p>",
"    For patients with a good performance status (ie, ECOG &le;3) who choose not to participate in a clinical trial, we suggest the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    rather than methotrexate alone. The combination of methotrexate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    is an acceptable alternative.",
"   </p>",
"   <p>",
"    This is principally based upon the following randomized trial that demonstrated higher response rates with combination therapy: &nbsp;",
"   </p>",
"   <p>",
"    An international phase II trial of 79 patients age 18 to 75 years with PCL were randomly assigned treatment with four cycles of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (3.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) or the same dose of methotrexate plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice a day on days 2 to 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/27\">",
"     27",
"    </a>",
"    ]. Cycles of chemotherapy were administered every three weeks and were followed by whole-brain irradiation. When compared with those assigned to methotrexate alone, patients assigned the combination of methotrexate plus cytarabine had the following significant outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of complete (46 versus 18 percent) and overall response (69 versus 40 percent).",
"     </li>",
"     <li>",
"      Higher rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic toxicity (92 versus 15 percent). After an infective complication rate of 32 percent was identified among patients receiving combination therapy in the first step analysis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      support and antimicrobial prophylaxis were strongly recommended for patients receiving combination therapy.",
"     </li>",
"     <li>",
"      There were three toxic deaths among the patients receiving combination therapy arm and one among the patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous other regimens that incorporate systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    have been evaluated in patients with PCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II multicenter trial of 46 patients with newly diagnosed PCL evaluated induction chemotherapy with high dose systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       gm/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      followed by consolidation for patients who achieved a complete response with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus infusional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/28\">",
"       28",
"      </a>",
"      ]. At a median follow-up of 3.3 years, the following outcomes were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Twenty-nine patients (63 percent) attained a complete response with induction chemotherapy and proceeded to consolidation therapy.",
"     </li>",
"     <li>",
"      Median progression-free survival (PFS) was 2.3 years with estimated PFS rates of 73, 71, and 67 percent at 1, 2, and 3 years, respectively.",
"     </li>",
"     <li>",
"      Estimated overall survival rates were 73, 71, and 67 percent at 1, 2, and 3 years, respectively.",
"     </li>",
"     <li>",
"      There was one treatment-related mortality during consolidation (sepsis) and no evidence for significant early or delayed treatment-related neurotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another prospective phase II study (New Approaches for Brain Tumor Therapy NABTT 96-07) evaluated the administration of 8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      IV, followed by calcium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue, every 14 days until complete response, or to a maximum of 8 cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/20\">",
"       20",
"      </a>",
"      ]. If a partial or complete response was demonstrated on MRI, maintenance chemotherapy with methotrexate (8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      IV once per month was continued for 11 cycles, or until the occurrence of either unacceptable toxicity or evidence of disease progression. A report of 23 evaluable patients treated on this protocol, demonstrated the following results:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Overall response rate of 74 percent with 12 complete and 5 partial responses.",
"     </li>",
"     <li>",
"      Median progression-free and overall survival times of 12.8 and 23+ months, respectively.",
"     </li>",
"     <li>",
"      Toxicity was modest, with grade 4 toxicity seen in only four patients after 287 cycles of chemotherapy. Of the 19 patients who had at least one follow-up Mini-mental State Examination, only one declined from baseline, from 29 to 27.",
"      <br/>",
"      <br/>",
"      A follow-up report from this study indicated that 5 of the 12 patients (40 percent) who achieved a CR were still alive without disease progression after a median follow-up of 6.8 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter",
"      <span class=\"nowrap\">",
"       pilot/phase",
"      </span>",
"      II trial of a high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      -based treatment program, included",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , vinca alkaloids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and intraventricular treatment with methotrexate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , and cytarabine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/23\">",
"       23",
"      </a>",
"      ]. Of 61 evaluable patients, the overall response rate was 71 percent, with 61 percent complete remissions and a treatment-related mortality of 9 percent. At a median follow-up of 26 months, median survival was 50 months. Estimated five-year survival rates were 75 and 19 percent for those &lt;61 or &gt;60 years of age, respectively. Neurotoxicity was infrequent (3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another protocol, referred to as \"barrier modification\" chemotherapy, patients were given general anesthesia during which the osmotic blood-brain barrier underwent osmotic disruption by the intraarterial infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/4,24,30\">",
"       4,24,30",
"      </a>",
"      ]. Intraarterial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (2.5 g), and IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      were given concurrently, followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (24",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for 14 days.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      rescue was started 36 hours after methotrexate continued for five days. This cycle was repeated every 28 days for one year. Reported median overall survival was 44.5 months with preservation of cognitive functioning based on serial neuropsychological assessment. Risks of blood-brain barrier disruption include seizures, strokes, and cerebral edema. This approach is expensive and technically demanding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23594376\">",
"    <span class=\"h3\">",
"     Dose of methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with lower doses, higher dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    results in superior survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, a retrospective analysis of 357 patients reported in 19 prospective series, reported that patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      at doses &ge;3",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      had a significantly longer median survival compared with those receiving &lt;3",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/31\">",
"       31",
"      </a>",
"      ]. Of the 144 assessable patients, rates of complete remission (CR) were 64 and 38 percent for the higher and lower methotrexate doses, respectively.",
"     </li>",
"     <li>",
"      Somewhat similar results were noted in a multicenter study reporting on survival data in 370 patients treated at 23 different centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients treated with radiation therapy alone had the worst two-year overall survival (25 percent), whereas those treated with high doses of MTX and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      had the best survival (64 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with PCL, we suggest the use of high dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (ie, 3.5 to 8",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    either alone or in combination. Radiation is typically deferred in most patients, except in the subpopulation who have a contraindication to chemotherapy. The addition of radiation therapy is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Is there a role for radiation therapy?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The administration of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    must be performed at a center that has expertise in its use and appropriate laboratory support for the measurement of methotrexate levels. Adjustment for renal dysfunction is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Is there a role for radiation therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCL is extremely sensitive to radiation therapy, but its use in the initial treatment of PCL is controversial. Radiation alone had been the initial therapy of choice prior to studies of high-dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , which provided superior survival rates with less long-term toxicity. Radiation therapy remains an option for the palliative treatment of patients who are not candidates for high dose systemic chemotherapy. Radiation therapy is given after methotrexate-based chemotherapy at some centers to younger patients with a good performance status.",
"   </p>",
"   <p>",
"    Immediate complications from radiation are few and include headaches, hair loss, and cutaneous irritation. In patients with significant mass effect, corticosteroids should be administered to avoid cerebral edema and symptomatic elevation of intracranial pressure. Acute symptoms of confusion, caused by XRT-induced brain edema, are usually mild and transient. Occasionally, it may be necessary to temporarily increase the dose of corticosteroids to reduce the resulting edema. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Corticosteroids'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed symptoms, occurring within 7 to 40 days of XRT, are thought to result from inhibition of myelin synthesis. Such symptoms should be evaluated cautiously and thoroughly, since they can be easily misinterpreted as treatment failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     With chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the timing of whole brain radiation therapy (WBRT) for the treatment of PCL is controversial. Chemotherapy directly followed by radiotherapy has achieved high response rates, but older recipients of this combination suffer from severe toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/3,32-38\">",
"     3,32-38",
"    </a>",
"    ]. An alternative is to postpone whole brain radiation therapy until disease progression. This approach is supported by a retrospective analysis of 378 patients for whom there was no improvement in survival when whole brain radiotherapy was provided to patients after they achieved a complete response to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17\">",
"     17",
"    </a>",
"    ]. Studies of radiation in PCL have mostly investigated whole brain radiation therapy; but in theory stereotactic cranial radiosurgery may provide control of solitary recurrences.",
"   </p>",
"   <p>",
"    Our general treatment approach is to determine the need for radiation therapy based upon the response to systemic high-dose chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For younger patients who fail to achieve a complete response with &ldquo;first line&rdquo; systemic chemotherapy alone, we suggest the addition of a second chemotherapy agent or the addition of WBRT after completion of chemotherapy rather than waiting until the development of progressive disease.",
"     </li>",
"     <li>",
"      For those younger patients who achieve a complete response with systemic high-dose chemotherapy, we suggest postponing WBRT until the time of relapse rather than delivering it after the completion of chemotherapy. This preference places a high value on the preservation of quality-of-life and avoidance of neurotoxicity and places a low value on the small, yet uncertain increased chance of relapse without radiation therapy.",
"     </li>",
"     <li>",
"      For patients over age 60, we postpone WBRT until disease progression rather than delivering it after the completion of chemotherapy. This suggestion is largely based upon the high rate of neurotoxicity after WBRT plus chemotherapy in older adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A phase III trial enrolling 551 patients with newly diagnosed PCL randomly assigned therapy to six cycles of chemotherapy alone (intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    4",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ) or the same chemotherapy with WBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/39\">",
"     39",
"    </a>",
"    ]. Sixty-six patients (13 percent) died during initial chemotherapy. An intention-to-treat cohort consisted of 411 patients who completed first-line chemotherapy and had a known response status. Of these 93 patients had a major protocol violation, therefore 318 patients were included in a per-protocol treatment analysis, which demonstrated that patients who did not receive WBRT had similar median overall survival (37.1 and 32.4 months) and median progression-free survival (11.9 and 18.3 months, respectively) times yet higher rates of delayed neurotoxicity (71 versus 46 percent) when compared with those who did receive WBRT. An intent to treat analysis was not presented.",
"   </p>",
"   <p>",
"    Representative reports on the use of chemotherapy plus whole brain radiation therapy are outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective trial evaluated intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on days 1 and 8 plus 12 mg of intrathecal methotrexate via an Ommaya reservoir on days 1, 4, 8, 11, 15, and 18 given in conjunction with calcium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/3\">",
"       3",
"      </a>",
"      ]. This was followed by whole brain radiation (XRT) with 50.4 Gy (1.8 Gy fractions per day for 28 days), and cytosine arabinoside at a dose of 3",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on two consecutive days, beginning three weeks after the end of XRT.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      (16 mg per day) was started at the beginning of chemotherapy and tapered after completion of XRT. The following results were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete remission was seen in 87 percent.",
"     </li>",
"     <li>",
"      Median cause-specific survival was 42.5 months.",
"     </li>",
"     <li>",
"      Long-term toxicity included delayed XRT-related neurotoxicity (eg, memory impairment, gait failure, and incontinence) in 37 percent. This was especially prominent in patients older than 50 to 60 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a protocol employing high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (3.5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , followed by whole brain XRT and high-dose cytosine arabinoside, complete remission was attained in 87 percent, with an overall median survival of 60 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/33\">",
"       33",
"      </a>",
"      ]. In patients &gt;60 years of age, median survival with or without whole brain XRT was 32 and 33 months, respectively; late neurotoxicity was significantly more common in older patients receiving XRT. When whole-brain XRT was deferred in older patients, overall survival was not reduced, but there was less treatment-related toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cooperative multicenter",
"      <span class=\"nowrap\">",
"       RTOG/SWOG",
"      </span>",
"      study based on the above protocol enrolled 102 newly-diagnosed patients, using a slightly lower dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (2.5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       );",
"      </span>",
"      all patients received whole brain XRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/32\">",
"       32",
"      </a>",
"      ]. Complete and partial response rates to pre-irradiation chemotherapy were 58 and 36 percent, respectively, with significantly different overall median survivals of 50 versus 22 months in those &lt;60 and &ge;60 years of age, respectively. Severe delayed neurologic toxicity was noted in 12 patients, eight of whom died.",
"     </li>",
"     <li>",
"      In a multicenter phase II trial, 30 patients &lt;65 years of age received sequential treatment with systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      , followed by high-dose chemotherapy (HDT), autologous hematopoietic cell transplantation (HCT), and hyperfractionated whole brain radiotherapy (WBRT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/41\">",
"       41",
"      </a>",
"      ]. At a median follow-up of 63 months, five-year overall survival was 69 percent for all patients and 87 percent for the 23 patients receiving HDT plus autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/41\">",
"       41",
"      </a>",
"      ]. Five of the 21 patients who completed therapy, including WBRT, developed leukoencephalopathy. Their median age was 59 years (range: 44 to 62).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major drawback to the use of whole brain radiation therapy in conjunction with chemotherapy for patients with PCL is the high incidence of cognitive worsening and white matter damage. As an example, a retrospective analysis of 185 patients with PCL treated with chemotherapy plus whole brain radiation therapy reported a five-year cumulative incidence of neurotoxicity of 24 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/42\">",
"     42",
"    </a>",
"    ]. Other studies have reported even higher frequencies of clinical neurotoxicity with regimens that include WBRT; but it remains uncertain whether there is a 'safe dose' of radiation in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurotoxicity presented as a rapidly progressive dementia that developed after a variable delay from the end of combined modality treatment. Early cognitive dysfunction was followed by motor and autonomic symptoms, including gait ataxia and incontinence. Risk factors for development of neurotoxicity on univariate analysis included older age, mental status changes at diagnosis, female sex, and radiotherapy, while only radiotherapy remained as an independent risk factor on multivariate analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     For palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCL is extremely sensitive to radiation therapy, and radiation plus corticosteroids may be used for the palliation of patients who are not candidates for chemotherapy. Complete radiographic and clinical responses can be obtained in most patients treated with standard fractionation to 20 to 40 Gy. However, despite this rapid response, the disease tends to recur in &gt;90 percent of patients within one year of treatment, with a median survival time of 23 versus 6 to 8 months for those less than or greater than 60 years of age, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Radiation Therapy Oncology Group (RTOG) reviewed the outcome of patients treated with 40 Gy to the whole brain followed by a 20 Gy boost to the involved area. They concluded that XRT is associated with a high rate of post-treatment local disease recurrence, significant MRI white matter changes and cognitive impairment, and lack of significant improvement in disease-free survival. The quality of life was not assessed in these studies.",
"   </p>",
"   <p>",
"    Cranial radiation can be associated with acute, delayed, and late complications that are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are unable to tolerate high-dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , we suggest the consideration of alternative chemotherapy regimens (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or an anti-folate agent other than methotrexate) or high dose chemotherapy followed by autologous marrow support. Palliation can be provided with whole brain radiation or corticosteroids alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9112617\">",
"    <span class=\"h2\">",
"     Is there a role for transplant?",
"    </span>",
"    &nbsp;&mdash;&nbsp;While high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based induction chemotherapy prolongs survival over whole brain radiation therapy alone, at least half of patients with PCL who achieve a complete response will relapse within five years. Relapse likely results from residual systemic malignant cells that are below the limits of detection using flow cytometry of peripheral blood and combined positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    imaging. High dose chemotherapy supported by autologous hematopoietic cell transplantation (HCT) is being investigated in an attempt to eliminate this residual disease. We consider this approach for younger patients with a good performance status who have achieved a complete response, ideally within the context of a clinical trial.",
"   </p>",
"   <p>",
"    As examples, two randomized trials have been designed to test whether myeloablative chemotherapy with HCT is superior to non-myeloablative chemotherapy. The first, NCT01511562 (CALGB 51101), randomizes patients to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    , and autologous stem cell transplantation",
"    <strong>",
"     or",
"    </strong>",
"    non-myeloablative consolidation chemotherapy comprising",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/47\">",
"     47",
"    </a>",
"    ]. The second, NCT01011920, randomizes patients to one of three MTX-based therapies after which complete responders are again randomized to either whole brain radiation of myeloablative chemotherapy with HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several single arm phase II trials of high dose chemotherapy and autologous HCT (rescue) in patients with newly diagnosed PCL suggest that these approaches are feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/41,49-56\">",
"     41,49-56",
"    </a>",
"    ]. The largest report was of 43 patients with newly diagnosed PCL enrolled on two prospective phase II trials of induction chemotherapy with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    followed by high-dose",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"      carmustine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"      thiotepa",
"     </a>",
"    </span>",
"    plus autologous HCT with or without whole brain radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/49\">",
"     49",
"    </a>",
"    ]. Following induction, 34 patients achieved complete remission. After a median follow-up of 10 years, estimated survival rates at two and five years were 81 and 70 percent, respectively, and median survival was approximately 8.5 years. Of the eight patients (19 percent) who developed neurotoxicity, all had received whole brain radiation therapy (WBRT). None of the patients who received HCT without WBRT developed neurotoxicity.",
"   </p>",
"   <p>",
"    However, late relapses occur, which suggests that the optimal conditioning regimen has yet to be defined. Toxicities from these myeloablative approaches include grade 3 to 4 neutropenia and thrombocytopenia, febrile neutropenia in approximately one-half of all recipients, and therapy-related deaths in 2 to 5 percent of those treated. These toxicities are no higher than those associated with high-dose chemotherapy and autologous HCT given patients with non-Hodgkin lymphoma outside the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial response rates of PCL to corticosteroids can be as high as 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/57\">",
"     57",
"    </a>",
"    ]. However, clinical and radiographic improvement is usually transient, and the disease tends to recur within a few months after discontinuation of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because treatment with corticosteroids may delay or interfere with diagnosis and alter the histopathology of the tumor, it is important that they not be used before pathological confirmation of biopsy results. If necessary, patients with symptomatic edema or increased intracranial pressure can be initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is the most commonly used preparation, and is often given at a starting dose of 4 mg PO four times per day. If radiation treatment is contemplated, corticosteroids should be continued at full doses until the radiation course has been completed. The dose can then be tapered.",
"   </p>",
"   <p>",
"    Concomitant administration of H2-blockers, calcium and vitamin D is usually recommended for patients receiving glucocorticoids. Blood glucose, potassium, and examination of the stool for occult blood should be monitored periodically during prolonged steroid therapy.",
"   </p>",
"   <p>",
"    Glucocorticoids increase the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , which may require dosage adjustments. Prolonged use of glucocorticoids can also result in immunosuppression and a subsequent increased frequency of infections. This is an important consideration in patients undergoing chemotherapy, who may be at additional risk because of chemotherapy-induced neutropenia. Patients taking high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for longer than two to three weeks should be considered for prophylactic antibiotics to prevent Pneumocystis pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PCL are at risk for seizures, but prophylactic anticonvulsants do not affect the frequency of subsequent seizures, and have deleterious interactions with cytotoxic drugs and corticosteroids. As with other brain tumors, we reserve the use of anticonvulsants for patients with documented seizure activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link&amp;anchor=H4#H4\">",
"     \"Seizures in patients with primary and metastatic brain tumors\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgical intervention in PCL is usually limited to stereotactic biopsy for tissue diagnosis. Extensive resection is usually impractical, given the deep location and multifocal nature of most of these tumors. There is also no evidence that extensive surgical resection provides removal of infiltrating margins of PCL.",
"   </p>",
"   <p>",
"    The median survival time of patients with PCL treated with surgery alone is less than four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/59\">",
"     59",
"    </a>",
"    ]. However, surgical resection may be considered in patients with an increased risk of herniation, impending hydrocephalus, uncontrolled mass effect, or in the unlikely event of a single, well-defined, and easily accessible lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for PCL apply to most disease presentations and patient populations. However, involvement of the eye or cerebrospinal fluid has unique therapeutic implications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of primary ocular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of intraocular lymphoma remains unclear and there is little consensus among ophthalmologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. Lacking prospective randomized trials comparing different therapies, the majority of data comes from retrospective analyses. Many experts advocate the use of therapy directed at the eye (ie, radiation therapy or intravitreal chemotherapy) in addition to systemic chemotherapy with high-dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (8",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV) every 14 days for four cycles with or without steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/62,67,68\">",
"     62,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular directed therapy has been added principally based upon the concern that it may be difficult to achieve active concentrations of chemotherapy in the eye with systemic therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/68\">",
"     68",
"    </a>",
"    ]. However, some patients with ocular involvement given systemic chemotherapy achieve sufficient concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in the vitreous and aqueous humor to provide a disappearance of cells in this location (ie, complete response) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients treated with intra-ocular therapy in addition to systemic therapy appear to have a longer median progression free survival, but similar overall survival rates when compared with those who do not receive dedicated ocular therapy.",
"   </p>",
"   <p>",
"    The benefit of dedicated ocular therapy was reviewed in an international retrospective series that included 221 HIV-negative, immunocompetent patients with PCL with intraocular involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/69\">",
"     69",
"    </a>",
"    ]. Treatment information was available for 176 patients and included dedicated ocular therapy in 102 patients (ocular radiotherapy in 79 patients, intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in 22 patients) in addition to more global treatment of their brain lymphoma. Patients who received dedicated ocular therapy had significantly longer median progression free survival (19 versus 15 months), but no difference in median overall survival (31 months) when compared with those who did not receive dedicated ocular therapy. The pattern of treatment failure did not differ between these two groups. Sites of progression included the brain, eyes, brain and eyes, or systemic disease in 52, 19, 12, and 2 percent, respectively.",
"   </p>",
"   <p>",
"    The preferred dedicated ocular therapy remains to be determined. Either ocular radiation or intravitreal chemotherapy can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular radiation &mdash; Ocular radiation, given at a total radiation dose of 35 to 40 Gy fractionated over five weeks, has been the standard therapy for many years. Patients require treatment of both eyes and will have an improvement in their vision with vitreal clearing; but it is frequently followed by xerophthalmia and chemosis. Cataracts, corneal ulcerations, and retinal injuries are uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H33#H33\">",
"       \"Complications of cranial irradiation\", section on 'Xerophthalmia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravitreal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      &mdash; A prospective trial evaluated the use of intravitreal methotrexate (400 micrograms in a total volume of approximately 0.1 mL) twice weekly until response is achieved, followed by weekly injections for one month, and then monthly injections for one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/72\">",
"       72",
"      </a>",
"      ]. In a follow-up study of 16 HIV-negative patients with intraocular B cell lymphoma, all 26 involved eyes were cleared clinically of malignant cells after a maximum of 12 intravitreal injections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/73\">",
"       73",
"      </a>",
"      ]. Side effects were common, and included cataract, corneal epitheliopathy, and maculopathy; no patient had irreversible loss of vision that could be definitely attributed to the methotrexate injections. The intravitreous administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in this population is under exploration.",
"     </li>",
"     <li>",
"      Intravitreal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; The anti-CD20 monoclonal antibody, rituximab, has become a standard component of the initial systemic therapy for patients with CD20 positive lymphomas. Small case series have suggested that intravitreal rituximab is safe and has activity against primary intraocular lymphoma when administered alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with PCL with ocular involvement, we suggest the administration of dedicated ocular therapy (either radiation or intravitreal chemotherapy) in addition to systemic therapy, rather than systemic therapy alone. Alternatively, dedicated ocular therapy may be reserved for those patients who do not obtain a complete response (CR) with high-dose systemic chemotherapy alone.",
"   </p>",
"   <p>",
"    Ocular radiation therapy is the most commonly used dedicated ocular therapy given its ease of administration, but intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is an acceptable alternative. A total radiation dose of 35 to 40 Gy is fractionated over five weeks. Most patients require treatment of both eyes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment of leptomeningeal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with patients with other types of PCL, patients with leptomeningeal lymphoma are primarily treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . It may be given intrathecally, either by Ommaya reservoir or lumbar puncture (12.5",
"    <span class=\"nowrap\">",
"     mg/dose",
"    </span>",
"    twice per week), until malignant cells are no longer detected in the CSF. Thereafter, at least two more doses are given. Alternatively, high doses of methotrexate (8",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    may be given by the intravenous route. The latter routinely provides CSF levels between 10",
"    <sup>",
"     -5",
"    </sup>",
"    and 10",
"    <sup>",
"     -6",
"    </sup>",
"    molar for 36 hours.",
"   </p>",
"   <p>",
"    Alternative therapies include intrathecal slow release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (DepoCyt), 4-hydroxyperoxycyclophosphamide, or systemic chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/67\">",
"     67",
"    </a>",
"    ]. Radiotherapy is usually deferred in order to salvage relapsed disease or to treat focal areas of symptomatic tumor. Intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is currently under investigation for leptomeningeal dissemination in patients with B cell lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of older adults (eg, those over 60 years) with PCL is controversial. As always, patients should be encouraged to participate in clinical trials, when available. As described above, younger patients with PCL are primarily treated with high-dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or methotrexate-based chemotherapy with or without whole brain radiation therapy (XRT). Side effects from XRT, especially delayed neurotoxicity, limit its use in older adults. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Is there a role for radiation therapy?'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinicians often have concerns over the ability of older adults to tolerate intensive chemotherapy and XRT. The management of PCL in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The complexities of treating older adults with PCL were highlighted in a randomized phase III trial that investigated the role of XRT in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/39,76\">",
"     39,76",
"    </a>",
"    ]. Accrual was slow, consistent with the theory that physicians have biases that shape the care of older patients. Of the 126 patients enrolled who were age 70 or greater, only 66 were treated per protocol, suggesting that many institutions were not capable of adapting methotrexate-based regimens to treat older adults. In addition, correlative data regarding drug levels suggested that the methotrexate dose used may have been too low. As such, it is difficult to interpret the results and apply them to a larger population. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'With chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following sampling of studies has evaluated the treatment of older adults with PCL: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial investigated the use of high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and CCNU in 30 older adults (median age 70 years) with PCL and a median Karnofsky performance status of 60 percent (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/77\">",
"       77",
"      </a>",
"      ]. Whole brain irradiation was reserved for patients not responding to chemotherapy. The best-documented response was a complete response, partial response, or progressive disease in 44, 26, and 30 percent, respectively. At a median follow-up of 78 months, the five-year overall survival rate was 33 percent.",
"     </li>",
"     <li>",
"      Another prospective trial from the same institution evaluated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"       lomustine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-MCP) in 28 older adults (median age 75 years) with PCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/78\">",
"       78",
"      </a>",
"      ]. Whole brain irradiation was reserved for patients not responding to chemotherapy. The best-documented response was a complete response, partial response, stable disease, or progressive disease in 64, 18, 4, and 7 percent, respectively. At a median follow-up of 36 months, the three-year overall survival rate was 31 percent. Common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included leukopenia (93 percent), thrombocytopenia (43 percent), and increased ALT (25 percent).",
"     </li>",
"     <li>",
"      A retrospective analysis of 174 older adults (&ge;65 years) from Memorial Sloan-Kettering Cancer Center with newly diagnosed PCL reported a median overall survival of 25 months and a three-year survival rate of 36 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/79\">",
"       79",
"      </a>",
"      ]. Approximately 20 percent of patients were alive for more than 10 years. Patients were treated with chemotherapy alone (117 patients), chemotherapy plus radiation (31 patients), or radiation alone (16 patients). Treatment-related neurotoxicity at two years was higher among those whose therapy included radiation.",
"     </li>",
"     <li>",
"      A retrospective analysis of 31 patients with PCL who were age 70 years or older at the time of diagnosis and were treated with systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (3.5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      to 8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      reported that 88 percent of the 303 cycles given required dose reduction due to impaired creatinine clearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/26\">",
"       26",
"      </a>",
"      ]. Overall response rate was 97 percent (60 percent complete). Toxicity was generally mild with gastrointestinal disturbances, hematological complications, and renal toxicity seen in 58, 81, and 29 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who are candidates for chemotherapy, we suggest initial high-dose systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based therapy as used for younger patients. For patients over age 60, we also suggest postponing whole brain radiation therapy until the time of progressive disease rather than delivering it after the completion of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patients with renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be safely administered to patients with mild to moderate renal insufficiency if appropriate dose reductions are used. Methotrexate should be avoided in patients with a creatinine clearance less than 30",
"    <span class=\"nowrap\">",
"     mL/minute.",
"    </span>",
"    Dose adjustments for high dose methotrexate in patients with renal insufficiency are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Renal function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis investigated the use of high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (3.5 to 8",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    in 31 older adults (median age 74 years) with PCL, many of whom had renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/26\">",
"     26",
"    </a>",
"    ]. Overall, 88 percent of cycles required dose reduction because of impaired creatinine clearance. The overall response rate was 97 percent (60 percent complete). Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities were uncommon and included hematologic complications (7 percent), gastrointestinal disturbances (3 percent), and cardiac complications (3 percent). There were no grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    renal toxicities.",
"   </p>",
"   <p>",
"    For most patients with renal insufficiency, we suggest the use of dose-adjusted high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    based upon creatinine clearance. Radiation plus corticosteroids may be used for the palliation of patients who are not candidates for high dose methotrexate. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'For palliation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment of PCL, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse and long-term treatment toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated no more than two months after the completion of planned therapy to determine their response to treatment. This evaluation includes gadolinium-enhanced MRI scans with measurement of disease using either uni-dimensional or cross-sectional measurements. Patients who had involvement of the eye or cerebrospinal fluid at the time of diagnosis should undergo repeat ophthalmologic examination and lumbar puncture, respectively. Otherwise, these studies are reserved for patients with symptoms suggesting eye or CSF involvement. If the CSF is examined, patients with an Ommaya reservoir should have samples taken from both the reservoir and a lumbar puncture.",
"   </p>",
"   <p>",
"    An interdisciplinary, international consensus group has devised the following response criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete response (CR) is obtained if there is complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI and the patient has not received any corticosteroids for at least two weeks. Patients who had prior ocular involvement should have no evidence of active ocular lymphoma. Patients with previous cerebrospinal fluid (CSF) involvement should have negative CSF studies.",
"     </li>",
"     <li>",
"      A complete response, unconfirmed (CRu) is documented if the patient otherwise meets criteria for a CR but continues to require corticosteroids. The term CRu is also used for patients with a small but persistent enhancing abnormality on MRI, thought to be related to biopsy or focal hemorrhage or for patients with a persistent minor abnormality on ophthalmologic examination.",
"     </li>",
"     <li>",
"      A partial response (PR) is documented for patients who meet all of the following criteria: no new sites of disease, at least a 50 percent decrease in the contrast-enhancing lesion seen on MRI compared with baseline, and a decrease in the vitreous cell count or",
"      <span class=\"nowrap\">",
"       retinal/optic",
"      </span>",
"      nerve cellular infiltrate. CSF cytology may continue to show persistent malignant or suspicious cells and patients may be receiving corticosteroid treatment.",
"     </li>",
"     <li>",
"      Stable disease (SD) is that which does not meet the criteria for CR, CRu, PR, or progressive disease.",
"     </li>",
"     <li>",
"      Progressive disease (PD) is documented if any of the following are noted: there is a more than 25 percent increase in the contrast-enhancing lesion seen on MRI, an increase in the vitreous cell count, progressive retinal or optic nerve infiltration, new lesions in an old site or involvement of a new site of disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surveillance for relapse or treatment complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. Our approach is based upon the following understandings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of relapses occur during the first five years after completion of treatment.",
"     </li>",
"     <li>",
"      The majority of patients with PCL who experience a relapse will have a local recurrence within the brain or throughout the neuraxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subarachnoid space is a site for relapse with subsequent development of leptomeningeal disease. The eye is also a potential site of relapse, while very few spinal cord relapses occur. Systemic dissemination occurs in 7 to 10 percent of patients with advanced PCL and tends to involve extranodal organs, such as kidneys, skin, testicles, and uterus.",
"   </p>",
"   <p>",
"    Accordingly, patients with PCL should be monitored closely for evidence of worsening neurologic status, development of new deficits, or recurrence of previously resolved symptoms signaling disease progression, recurrence, or dissemination.",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every three months during the first two years, every six months for the next three years, and then annually for at least five years. At these visits we perform a history and physical examination, including a mini-mental status examination, and a gadolinium-enhanced MRI of the brain. Evaluation of the eyes and CSF is performed based upon symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Radiation toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed CNS toxicity is common when chemotherapy is combined with radiation, especially in older patients. While there is no known treatment or preventative measures, early detection will allow for early intervention. As such, we routinely screen with a composite of examinations that evaluate attention, executive functions, verbal memory, and motor speed. The International PCNSL Collaborative Group (IPCG) has developed a neurocognitive battery that is recommended for follow-up of patients treated on clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Is there a role for radiation therapy?'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Glucocorticoid toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to prolonged steroid therapy are well known. Of particular interest is glucocorticoid-induced myopathy. It is characterized by proximal weakness, especially in the lower extremities. Treatment includes dose reduction to the lowest possible level,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alternate-day therapy. Adequate diet and exercise should aid in recovery, which may take weeks to months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF REFRACTORY OR RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients are followed routinely to investigate for signs of progressive or relapsed disease. Patients should be reevaluated at the time of progression with a gadolinium-enhanced MRI of the brain, lumbar puncture, and slit lamp examination of both eyes. Since systemic disease occurs in 7 to 10 percent of PCL patients, chest and abdominopelvic CT scans of",
"    <span class=\"nowrap\">",
"     CT/PET",
"    </span>",
"    should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Throughout the course of the disease, the patient should be educated about the nature of his illness and actual expectations. During the terminal stages, adequate ancillary support and hospice care should be provided.",
"   </p>",
"   <p>",
"    Cranial irradiation should be reserved for non-responders to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or in cases of disease recurrence without response to repeated treatment with methotrexate or alternative chemotherapy.",
"   </p>",
"   <p>",
"    Treatment of patients with refractory or relapsed PCL is limited. Therapeutic options at relapse include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (ie, 3 to 8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      or methotrexate-based combination chemotherapy if there has been a prior complete remission with this agent. This selected group of patients has a high likelihood of achieving a second response to methotrexate.",
"     </li>",
"     <li>",
"      Alternative chemotherapy regimens (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]), including high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT).",
"     </li>",
"     <li>",
"      Whole brain radiation therapy in previously non-irradiated patients. Stereotactic radiotherapy may be an option for patients who have received whole brain radiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     High-dose methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who were previously treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    alone, repeat high dose methotrexate should be attempted, and will result in more than one-half of the patients achieving complete response. This was best illustrated in a retrospective multi-institution analysis that reported complete responses after retreatment with high-dose methotrexate in 16 of 22 patients in first relapse and in two of four patients in second relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/84\">",
"     84",
"    </a>",
"    ]. Median survival was 62 months after first relapse and 92 months overall. Toxicity was primarily hematologic, with 10 episodes of grade 3 or 4 toxicity during 566 cycles of methotrexate chemotherapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Methotrexate-based induction chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Salvage therapy with other chemotherapy agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients treated with chemotherapy without radiation, alternative chemotherapeutic protocols may be considered. Options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    , high dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Temozolomide plus rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports and two retrospective case series have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with PCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    A retrospective series evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, 15, and 22) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 7 and 15 to 21) in 15 patients with relapsed or refractory PCL (median age 69 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The objective response rate was 53 percent with a median overall survival of 14 months and a median progression-free survival of responding patients of 7.7 months. Side effects included myelosuppression with severe thrombocytopenia, anemia, and leukopenia seen in 4, 1, and 1 patients, respectively.",
"   </p>",
"   <p>",
"    A second retrospective series of seven patients with PCL evaluated a different schedule of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/12\">",
"     12",
"    </a>",
"    ]. Five patients achieved a complete radiologic response while two had partial responses. The median survival was eight months (range three to over 12 months) and the median response duration was six months. The most common side effect was myelosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Topotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pilot study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    at a dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV on days one through five of a 21-day cycle was administered to 15 immunocompetent patients with refractory or relapsed PCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/85\">",
"     85",
"    </a>",
"    ]. Six patients had a response (40 percent), with three being complete. Grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    toxicities included thrombocytopenia (three patients), neutropenia (11 patients). Median overall survival was 32 months while median progression-free survival was two months.",
"   </p>",
"   <p>",
"    In a second study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV on days 1 through 5 every four weeks) was given to 16 patients with PCL, 15 of whom had refractory or relapsed disease and had been previously treated with up to three chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/86\">",
"     86",
"    </a>",
"    ]. Complete and partial remissions were obtained in four and two patients, respectively, with progression-free survivals at 6 and 12 months of 20 and 13 percent, respectively. Two patients with pre-existing late neurotoxicity, both of whom had received prior whole brain radiation, died shortly after initiation of treatment with topotecan, despite an early response to the drug.",
"   </p>",
"   <p>",
"    The main toxicity in both studies has been grade III and IV neutropenia. As this agent has documented activity in relapsed and refractory disease, it might be considered for combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in the treatment of newly diagnosed patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13661788\">",
"    <span class=\"h3\">",
"     Pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    is a multitargeted antifolate with a broader spectrum of activity than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Animal studies suggest that intravenous pemetrexed has limited distribution in the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/87\">",
"     87",
"    </a>",
"    ]. The use of pemetrexed in PCL is considered experimental. A small prospective single center study evaluated the use of pemetrexed in 11 patients with relapsed or refractory PCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/88\">",
"     88",
"    </a>",
"    ]. Pemetrexed 900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    was administered every three weeks along with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , folate, and B12 supplementation. Responses were seen in six patients (55 percent) with four complete (36 percent). The median progression-free and overall survivals were 5.7 and 10.1 months, respectively. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities were thrombocytopenia (5 patients), leukopenia (4 patients), and anemia (3 patients). There were two infectious treatment-related deaths. Further studies are needed to determine the optimal dosing and efficacy of this agent in PCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited data on the efficacy of high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) in patients with relapsed or refractory PCL. The following is a survey of studies that have reported on the outcomes with this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study of 22 patients with refractory or relapsed intraocular lymphoma or PCL there was a three-year overall survival of 60 percent following high dose chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) and autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/89,90\">",
"       89,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second prospective trial examined the use of two cycles of high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      as salvage treatment followed by intensive chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      followed by autologous HCT rescue in 43 patients with relapsed, refractory, or partial responses to previous high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/91\">",
"       91",
"      </a>",
"      ]. Three patients died during salvage treatment related to septic shock or mesenteric necrosis. At a median follow-up of 36 months, median survival was 18.3 months. Two-year overall and progression-free survival rates were 45 and 43 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective, randomized trials are needed to compare this treatment approach to less intensive salvage therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole brain radiation therapy (WBRT) is indicated in patients who did not respond to initial treatment with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or who have relapsed. Two retrospectives studies have found that WBRT is associated with either a complete or partial response in 75 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Survival was reportedly significantly longer in those with a complete response (28 versus 4 to 5 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, superior outcomes were noted in patients less than 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Treatment-associated neurotoxicity (15 to 22 percent), such as cognitive symptoms, was more common among those exposed to a total radiation dose &gt;36 Gy, patients treated within six months of receiving methotrexate, and those older than 60 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrespective of treatment modality, several factors appear to influence patient outcome and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17,32,67,80,94-98\">",
"     17,32,67,80,94-98",
"    </a>",
"    ]. Of these, the most consistent prognostic factors are age and performance status. In order to adequately assess patients with this disorder, standardized systems for prognosis have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17,99\">",
"     17,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a prognostic scoring system based on the results of a multicenter study as well as responses to a questionnaire sent to members of the International Extranodal Lymphoma study group reported the following five adverse prognostic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17,99\">",
"     17,99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60 years",
"     </li>",
"     <li>",
"      ECOG performance status &gt;1",
"     </li>",
"     <li>",
"      Elevated serum level of lactate dehydrogenase",
"     </li>",
"     <li>",
"      Elevated CSF protein concentration",
"     </li>",
"     <li>",
"      Involvement of deep regions of the brain (periventricular regions, basal ganglia, brainstem,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cerebellum)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this proposed system, one point is given for the presence of each of these five adverse factors. For the 105 assessable patients in whom complete information was present, two-year overall survivals for overall scores of zero to one, two to three, and four to five were 80, 48, and 15 percent, respectively. For the 75 patients who received high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based chemotherapy with or without radiation therapy, two-year overall survivals were 85, 57, and 24 percent, respectively.",
"   </p>",
"   <p>",
"    Histopathologically, negativity of the malignant lymphocytes for the bcl-2 oncogene, expression of BCL-6, and small cell cleaved tumors have been associated with longer survival and slower disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/32,100,101\">",
"     32,100,101",
"    </a>",
"    ]. Uncleaved cell histology is associated with shorter survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/80\">",
"     80",
"    </a>",
"    ]. The presence or extent of mitotic figures, reticulin deposits, or histiocytes does not appear to influence disease course or survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/80\">",
"     80",
"    </a>",
"    ]. Outcome of patients with the much less common T cell PCL appears to be similar to that of B cell PCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytogenetic evaluation reveals del(6)(q22) and BCL-6 rearrangements in 45 and 17 percent of patients, respectively; each of these abnormalities is individually associated with shorter overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    resistance as a potential prognostic factor in DLBCL was evaluated in a study of the reduced folate carrier, the major route of cellular uptake of methotrexate. Methylation of the promoter region of the reduced folate carrier gene was found in nine patients with PCNSL treated with high-dose methotrexate-based chemotherapy, none of whom survived for more than three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/1/37914/abstract/104\">",
"     104",
"    </a>",
"    ]. In the 28 similarly-treated patients without methylation of this promoter region, three-year survival was 31 percent. While these differences were not statistically significant, they suggest additional avenues for approaching initial treatment of this disease, similar to those taken in the treatment of childhood acute lymphoblastic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37753?source=see_link&amp;anchor=H15#H15\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\", section on 'Drug metabolism and resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10260714\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     United States National Institutes of Health",
"    </a>",
"    (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary central nervous system lymphoma (PCL) is an uncommon variant of extranodal non-Hodgkin lymphoma that can involve the brain, leptomeninges, eyes, or spinal cord without evidence of systemic disease. Untreated PCL has a rapidly fatal course, with survival of approximately 1.5 months from the time of diagnosis. Survival after whole brain radiation therapy ranges from 12 to 18 months, but increases to an average of 36 to 48 months following chemotherapy alone or chemotherapy followed by radiation. However, whole brain radiation therapy (WBRT), especially in elderly patients with PCL, is associated with a high incidence of symptomatic neurotoxicity.",
"   </p>",
"   <p>",
"    The optimal treatment of PCL is unknown and there is variation in clinical practice. Patients should be encouraged to participate in clinical trials, when available. The general treatment principles for PCL apply to most disease presentations and patient populations. However, involvement of the eye, cerebrospinal fluid, or nerve roots may have unique therapeutic implications. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Special scenarios'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    PCL is primarily treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based induction chemotherapy. Optimal consolidative therapy remains undefined. Options include additional chemotherapy, WBRT, and high-dose chemotherapy followed by autologous hematopoietic cell transplantation",
"    <span class=\"nowrap\">",
"     (HDT/HCT).",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Induction",
"      </strong>",
"      &mdash; Treatment is indicated for patients with PCL to prolong survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are candidates for chemotherapy, we recommend high-dose systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -based induction therapy, rather than WBRT alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with good performance status (ie, ECOG &le;3) who choose not to participate in a clinical trial, we suggest the combination of methotrexate plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      rather than methotrexate alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Acceptable alternative regimens include methotrexate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (MTR) or rituximab, methotrexate,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      (R-MPV). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Methotrexate-based induction chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are unable to tolerate high-dose systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      for induction therapy, options include: alternative chemotherapy regimens (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ; or an anti-folate agent other than methotrexate) or palliative approaches. Palliation can be provided with whole brain radiation or corticosteroids alone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'For palliation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Consolidation",
"      </strong>",
"      &mdash; Optimal consolidation therapy in patients who achieve a complete response has not been defined. Options include chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ),",
"      <span class=\"nowrap\">",
"       HDT/HCT,",
"      </span>",
"      or WBRT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For younger patients who achieve a complete response with systemic high-dose chemotherapy, we suggest postponing whole brain radiation therapy until the time of relapse rather than delivering it after the completion of chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'With chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients over age 60 are at high risk of radiation-induced symptomatic neurotoxicity. For these patients, we suggest postponing WBRT until there is disease progression, rather than delivering it after completion of chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'With chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Resistant disease",
"      </strong>",
"      &mdash; For younger patients who fail to achieve a complete response with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -based chemotherapy, a second chemotherapy regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) can be given.",
"      <span class=\"nowrap\">",
"       HDT/HCT",
"      </span>",
"      is an acceptable alternative for patients with an initial partial response. For such patients, we also consider the addition of WBRT after completion of chemotherapy rather than waiting until the development of progressive disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'With chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Follow-up",
"      </strong>",
"      &mdash; After completion of the initially planned treatment of PCL, it should not be assumed that a &ldquo;cure&rdquo; has been established. Patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse and long-term treatment toxicities. We follow the consensus-based guidelines published by the International PCL Collaborative Group (IPCG). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Relapse",
"      </strong>",
"      &mdash; Therapeutic options at relapse include retreatment with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      if there had been a prior complete remission with this agent, alternative chemotherapy regimens (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ),",
"      <span class=\"nowrap\">",
"       HDT/HCT",
"      </span>",
"      and WBRT. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of refractory or relapsed disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/1\">",
"      Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/2\">",
"      Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/3\">",
"      Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/4\">",
"      Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996; 46:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/5\">",
"      Dahlborg SA, Petrillo A, Crossen JR, et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 1998; 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/6\">",
"      Schlegel U, Pels H, Glasmacher A, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001; 71:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/7\">",
"      Blay JY. [Primary cerebral non-Hodgkin lymphoma in non-immunocompromised subjects]. Bull Cancer 1997; 84:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/8\">",
"      Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology (Williston Park) 1998; 12:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/9\">",
"      Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/10\">",
"      O'Neill BP, O'Fallon JR, Earle JD, et al. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995; 33:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/11\">",
"      Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/12\">",
"      Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/13\">",
"      Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/14\">",
"      Wong ET. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2005; 64:934; author reply 934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/15\">",
"      Santisteban M, Nieto Y, De la Cruz S, et al. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol 2007; 9:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/16\">",
"      Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011; 76:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/17\">",
"      Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/18\">",
"      Shibamoto Y, Ogino H, Suzuki G, et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004. Neuro Oncol 2008; 10:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/19\">",
"      Joerger M, Huitema AD, Kr&auml;henb&uuml;hl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/20\">",
"      Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/21\">",
"      Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002; 51:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/22\">",
"      Herrlinger U, K&uuml;ker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005; 57:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/23\">",
"      Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21:4489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/24\">",
"      Fliessbach K, Helmstaedter C, Urbach H, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005; 64:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/25\">",
"      Doolittle ND, Petrillo A, Bell S, et al. Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program. J Neurosci Nurs 1998; 30:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/26\">",
"      Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/27\">",
"      Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/28\">",
"      Rubenstein JL, Johnson JL, Jung S, et al. Intensive chemotherapy and immunotherapy without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: Results of CALGB 50202 (abstract 763). Blood 2010; 116:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/29\">",
"      Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 2008; 70:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/30\">",
"      Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009; 27:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/31\">",
"      Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 2001; 51:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/32\">",
"      DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20:4643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/33\">",
"      Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/34\">",
"      Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21:4483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/35\">",
"      Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005; 64:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/36\">",
"      O'Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006; 64:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/37\">",
"      Ferreri AJ, Dell'Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/38\">",
"      Motomura K, Natsume A, Fujii M, et al. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma 2011; 52:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/39\">",
"      Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/40\">",
"      Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24:4570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/41\">",
"      Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/42\">",
"      Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005; 62:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/43\">",
"      Schuurmans M, Bromberg JE, Doorduijn J, et al. Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. Br J Haematol 2010; 151:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/44\">",
"      Ferreri AJ, Verona C, Politi LS, et al. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 2011; 80:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/45\">",
"      Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/46\">",
"      Laack NN, Ballman KV, Brown PB, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 2006; 65:1429.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01511562 (Accessed on July 20, 2012).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01011920 (Accessed on July 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/49\">",
"      Kasenda B, Schorb E, Fritsch K, et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol 2012; 23:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/50\">",
"      Illerhaus G, M&uuml;ller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/51\">",
"      Brevet M, Garidi R, Gruson B, et al. First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 2005; 75:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/52\">",
"      Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/53\">",
"      Montemurro M, Kiefer T, Sch&uuml;ler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/54\">",
"      Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21:4151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/55\">",
"      Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/56\">",
"      Kiefer T, Hirt C, Sp&auml;th C, et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol 2012; 23:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/57\">",
"      Ferracini R. [Primary malignant non-Hodgkin's lymphomas of the central nervous system in immunocompetent patients: diagnostic, prognostic and therapeutic criteria]. Pathologica 1997; 89:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/58\">",
"      Bromberg JE, Siemers MD, Taphoorn MJ. Is a \"vanishing tumor\" always a lymphoma? Neurology 2002; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/59\">",
"      Krogh-Jensen M, d'Amore F, Jensen MK, et al. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO. Ann Oncol 1994; 5:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/60\">",
"      Sonstein W, Tabaddor K, Llena JF. Solitary primary CNS lymphoma: long term survival following total resection. Med Oncol 1998; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/61\">",
"      Valluri S, Moorthy RS, Khan A, Rao NA. Combination treatment of intraocular lymphoma. Retina 1995; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/62\">",
"      Verbraeken HE, Hanssens M, Priem H, et al. Ocular non-Hodgkin's lymphoma: a clinical study of nine cases. Br J Ophthalmol 1997; 81:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/63\">",
"      Ferreri AJ, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 2002; 13:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/64\">",
"      Hormigo A, DeAngelis LM. Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma 2003; 4:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/65\">",
"      Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 2004; 126:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/66\">",
"      Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16:1589.",
"     </a>",
"    </li>",
"    <li>",
"     Rock JP, Cher L, Hochberg FH, et al. Primary CNS lymphoma. In: Neurological surgery, 4th ed, Yomans JR (Ed), WB Saunders, Philadelphia 1996. p.2688.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/68\">",
"      Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003; 9:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/69\">",
"      Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008; 71:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/70\">",
"      Grimm SA, Yahalom J, Abrey LE, DeAngelis LM. Retinopathy in survivors of primary central nervous system lymphoma. Neurology 2006; 67:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/71\">",
"      Kaushik M, Pulido JS, Schild SE, Stafford S. Risk of radiation retinopathy in patients with orbital and ocular lymphoma. Int J Radiat Oncol Biol Phys 2012; 84:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/72\">",
"      Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997; 115:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/73\">",
"      Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/74\">",
"      Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 2008; 126:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/75\">",
"      Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina 2009; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/76\">",
"      Roth P, Martus P, Kiewe P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012; 79:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/77\">",
"      Illerhaus G, Marks R, M&uuml;ller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/78\">",
"      Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011; 22:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/79\">",
"      Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010; 116:4605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/80\">",
"      Miller DC, Hochberg FH, Harris NL, et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994; 74:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/81\">",
"      Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/82\">",
"      Boiardi A, Silvani A, Pozzi A, Salmaggi A. Radiotherapy at tumor recurrence in primary CNS lymphoma. Neurology 1998; 50:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/83\">",
"      Chao ST, Barnett GH, Vogelbaum MA, et al. Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer 2008; 113:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/84\">",
"      Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10:5643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/85\">",
"      Voloschin AD, Betensky R, Wen PY, et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/86\">",
"      Fischer L, Thiel E, Klasen HA, et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004; 62:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/87\">",
"      Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther 2005; 315:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/88\">",
"      Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer 2012; 118:3743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/89\">",
"      Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/90\">",
"      Soussain C, Hoang-Xuan K, Levy V. [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bull Cancer 2004; 91:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/91\">",
"      Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle Osseuse-Th&eacute;rapie Cellulaire. J Clin Oncol 2008; 26:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/92\">",
"      Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005; 23:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/93\">",
"      Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007; 69:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/94\">",
"      Corry J, Smith JG, Wirth A, et al. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998; 41:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/95\">",
"      Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24:5711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/96\">",
"      Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer 2006; 106:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/97\">",
"      Brada M, Hjiyiannakis D, Hines F, et al. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998; 40:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/98\">",
"      Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/99\">",
"      Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/100\">",
"      Lin CH, Kuo KT, Chuang SS, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006; 12:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/101\">",
"      Levy O, Deangelis LM, Filippa DA, et al. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 2008; 112:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/102\">",
"      Shenkier TN, Blay JY, O'Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005; 23:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/103\">",
"      Cady FM, O'Neill BP, Law ME, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 2008; 26:4814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/1/37914/abstract/104\">",
"      Ferreri AJ, Dell'Oro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 2004; 126:657.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4706 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37914=[""].join("\n");
var outline_f37_1_37914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methotrexate-based induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23594407\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23594376\">",
"      - Dose of methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Is there a role for radiation therapy?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - With chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - For palliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9112617\">",
"      Is there a role for transplant?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of primary ocular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment of leptomeningeal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surveillance for relapse or treatment complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Radiation toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Glucocorticoid toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF REFRACTORY OR RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      High-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Salvage therapy with other chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Temozolomide plus rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Topotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13661788\">",
"      - Pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10260714\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4706|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/1/1043\" title=\"diagnostic image 1\">",
"      Primary CNS lymphoma MRI II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37753?source=related_link\">",
"      Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_1_37915="Parasomnias of childhood";
var content_f37_1_37915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parasomnias during sleep in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorders of arousal from NREM sleep",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parasomnias usually associated with REM sleep",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other parasomnias",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sleep-related movement disorders",
"       </td>",
"       <td class=\"subtitle1\">",
"        Isolated symptoms and normal variants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Confusional arousals",
"         </li>",
"         <li>",
"          Sleep terrors",
"         </li>",
"         <li>",
"          Sleep walking",
"         </li>",
"         <li>",
"          Parasomnia overlap disorder",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Nightmares",
"         </li>",
"         <li>",
"          REM sleep behavior disorder",
"         </li>",
"         <li>",
"          Parasomnia overlap disorder",
"         </li>",
"         <li>",
"          Sleep paralysis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Sleep enuresis (nocturnal enuresis)*",
"         </li>",
"         <li>",
"          Sleep-related groaning (catathrenia)",
"         </li>",
"         <li>",
"          Panic attacks",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Rhythmic movement disorder",
"         </li>",
"         <li>",
"          Bruxism",
"         </li>",
"         <li>",
"          Restless legs syndrome/periodic limb movement disorder",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Hypnic starts",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NREM: non-rapid eye movement; REM: rapid eye movement.",
"     <br/>",
"     * May occur during both NREM and REM sleep.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Suresh Kotagal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37915=[""].join("\n");
var outline_f37_1_37915=null;
var title_f37_1_37916="Prevention transmission HBV";
var content_f37_1_37916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82151%7EGAST%2F55845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82151%7EGAST%2F55845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for infected persons regarding prevention of transmission of HBV to others",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persons who are HBsAg-positive should:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have sexual contacts vaccinated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use barrier protection during sexual intercourse if partner not vaccinated or naturally immune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not share toothbrushes or razors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cover open cuts and scratches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clean blood spills with detergent or bleach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not donate blood, organs or sperms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children and adults who are HBsAg-positive:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can participate in all activities including contact sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should not be excluded from daycare or school participation and should not be isolated from other children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can share food, utensils, or kiss others",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright &copy; 2009 American Association for the Study of Liver Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for counseling and prevention of transmission of hepatitis B from individuals with chronic hepatitis B virus (HBV) infection:",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Carriers should be counseled regarding prevention of transmission of HBV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sexual and household contacts of carriers who are negative for HBV seromarkers should receive hepatitis B vaccination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Newborns of HBV-infected mothers should receive HBIG and hepatitis B vaccine at delivery and complete the recommended vaccination series",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Persons who remain at risk for HBV infection such as infants of HBsAg-positive mothers, health care workers, dialysis patients, and sexual partners of carriers should be tested for response to vaccination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Postvaccination testing should be performed at 9 to 15 months of age in infants of carrier mothers and one to two months after the last dose in other persons",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Follow-up testing of vaccine responders is recommended annually for chronic hemodialysis patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abstinence or only limited use of alcohol is recommended in hepatitis B carriers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persons who are positive only for anti-HBc and who are from a low endemic area with no risk factors for HBV should be given the full series of hepatitis B vaccine",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lok, ASF, McMahon, BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37916=[""].join("\n");
var outline_f37_1_37916=null;
var title_f37_1_37917="Contents: Cancer survivorship";
var content_f37_1_37917=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cancer survivorship",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cancer survivorship",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/41/16025\">",
"           Approach to the care of long-term testicular cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/12/5322\">",
"           Approach to the long-term survivor of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/34/28202\">",
"           Approach to the long-term survivor of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/54/14185\">",
"           Oral health in cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/6/32873\">",
"           Overview of cancer survivorship care for primary care and oncology providers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/5/4185\">",
"           Overview of care for adult survivors of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/34/36394\">",
"           Overview of the approach to the adult survivor of classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/44/35530\">",
"           The approach to hematopoietic cell transplantation survivorship",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43321\">",
"           The roles of diet, physical activity, and body weight in cancer survivorship",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-844C98A403-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_1_37917=[""].join("\n");
var outline_f37_1_37917=null;
var title_f37_1_37918="Exercise prescript schema";
var content_f37_1_37918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Exercise prescription schema for low back pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37918=[""].join("\n");
var outline_f37_1_37918=null;
var title_f37_1_37919="Cervical spinal stenosis";
var content_f37_1_37919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical spinal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the lack of white cerebrospinal fluid surrounding the spinal cord at C3-C5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jason E Decker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_1_37919=[""].join("\n");
var outline_f37_1_37919=null;
